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Abstract 
KRAS is one of the most frequently mutated genes across human cancers, including 
96% of pancreatic cancers, 40% of colorectal cancers, and 35% of lung cancers. The 
majority of human cancer cell lines and tumors from genetically engineered mouse 
models harboring an oncogenic mutant KRAS allele demonstrate a strong dependence 
on KRAS for proliferation and survival. This KRAS dependency is a type of ‘oncogene 
addiction,’ a state in which cancer cells depend on signaling from a single oncogene for 
survival. Unfortunately, the development of clinically effective KRAS-directed cancer 
therapies has been unsuccessful, and KRAS-mutant cancers are refractory to standard 
and targeted therapies. Alternative approaches to combatting KRAS-mutant cancers are 
clearly needed. We postulate that oncogenic KRAS signaling induces changes in cell 
signaling networks that cause cells to become dependent on certain genes, termed a 
‘synthetic lethal’ interaction. Identifying these selective vulnerabilities would lend insight 
to the pathways altered in KRAS-mutant cancers and may inform novel strategies to 
target KRAS-addicted cancers. In this thesis, we systematically identify candidate co-
dependencies of oncogenic KRAS by analyzing genetic dependencies revealed by 
genome-scale RNAi screens across a large panel of cell lines. We highlight methods to 
facilitate candidate selection/validation and integrate analyses of gene-expression data 
and genome-scale CRISPR/Cas9 screens to nominate candidate co-dependencies for 
further study. In addition, we examine CRISPR-Cas9 screens to identify genes that 
modify sensitivity to small molecule MAPK pathway inhibition (MAPKi) in RAS-mutant 
cancers. We propose that suppression of the DOCK5-RAC1 pathway demonstrates a 
drug-conditional lethal interaction with small molecule MAPK pathway inhibitors in RAS-
mutant cancers. We believe that these data provide a foundation for further examination 
of genetic co-dependencies of oncogenic KRAS and the potential synthetic lethal 
interaction between DOCK5-RAC1 pathway suppression and MAPKi in RAS mutant 
cancers. 
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BRAFi BRAF inhibition 
Cas9 CRISPR associated protein 9 
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CRISPR Clustered regularly interspaced short palindromic repeats 
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GOF Gain-of-function 
HRAS Harvey rat sarcoma viral oncogene homolog 
ICGC International Cancer Genome Consortium 
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LOF Loss-of-function 
MAPK Mitogen activated protein kinase 
MAPKi MAPK pathway inhibition 
MEKi MEK1/2 inhibition 
NRAS neuroblastoma RAS viral oncogene homolog 
NSCLC Non-small cell lung cancer 
ORF Open reading frame 
p-ERK Phospho-ERK1/2 
PI3K Phosphatidylinositol 3-kinase 
PIP2 Phosphatidylinositol-4,5-bisphosphate 
PIP3 Phosphatidylinositol-3,4,5-triphosphate 
RAC1 Ras related botulinum toxin substrate 1 
RAL RAS-like GTPase 
RALGDS RAL guanine nucleotide dissociation stimulator 
RNAi RNA interference 
RTK Receptor tyrosine kinase 
gRNA Short guide RNA 
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shRNA Short hairpin RNA 
siRNA Small interfering RNA 
TCGA The Cancer Genome Atlas 
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Introduction 
Overview 
The RAS family of genes (KRAS, NRAS, and HRAS) are frequently mutated in human 
cancers, including nearly all pancreatic cancers, ~50% of colorectal cancers, ~30% of 
lung cancers, and ~30% of melanomas. RAS mutations are associated with poor 
prognosis, and are used to exclude patients from treatment with some targeted 
therapies. Most RAS-mutant cancers require RAS signaling for continued proliferation 
and survival. This phenomenon, termed “RAS addiction,” makes RAS an appealing 
target for therapeutic intervention. Unfortunately, pharmacologic approaches to directly 
target RAS proteins have not yet succeeded in clinic.  
An alternative strategy of targeted drug development for RAS-mutant cancers is to 
identify signaling pathways that become essential for cancer cell survival in the context 
of oncogenic RAS signaling. These ‘synthetic lethal’ interactions provide opportunities 
for rational drug development to treat RAS-mutant malignancies. Our laboratory and 
others have performed RNAi screens as an unbiased approach to identify synthetic 
lethal interactions with oncogenic KRAS1,2. These screens have led to several potential 
targets - including TBK1, PLK1, and WT1 - which are the focus of ongoing 
investigation3-8. Notably, TBK1 shows promise as a novel therapeutic target for KRAS-
driven malignancies. Preclinical studies using a small molecule inhibitor of TBK1 
achieved therapeutic responses in Kras-mutant GEMMs9. Additionally, studying TBK1 
has led to the discovery of a novel effector pathway of oncogenic KRAS, in which TBK1 
promotes KRAS-driven tumorigenesis by regulating an autocrine cytokine circuit. Such 
data support the idea that synthetic lethal genetic interactions can identify valuable 
therapeutic targets and broaden our understanding of critical mediators of oncogenic 
KRAS, motivating our interest in identifying further novel candidates.  
Prior RNAi screens for synthetic lethal interactions with oncogenic KRAS harbor 
several limitations: these screens were performed in a limited number of cell lines and 
lineages, and most were not performed at genetic saturation. We hypothesize that many 
synthetic lethal partners of oncogenic KRAS remain unidentified. Recent technological 
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advances have provided the means to perform comprehensive loss-of-function screens 
in mammalian cells using RNAi10-12 or clustered regularly interspaced short palindromic 
repeats (CRISPR)-Cas913-15 libraries. Our laboratory has performed genome-scale 
lentivirally-delivered short hairpin RNA (shRNA) screens across ~216 independent 
cancer cell lines12. This effort, termed Project Achilles, is among the most 
comprehensive genome-scale shRNA screens performed on human cancer cell lines, 
and provides an opportunity to identify novel pathways essential to the survival of 
KRAS-mutant cancer cells. Prior studies demonstrated that this data has sufficient 
power to identify co-dependent genetic interactions in a genotype or lineage-specific 
manner10,16,17. 
The RAS pathway 
The three RAS proto-oncogenes (HRAS, KRAS, and NRAS) encode four distinct but 
highly homologous ~21 kDa RAS proteins: HRAS, NRAS, KRAS4A and KRAS4B, 
where KRAS4A and KRAS4B are alternative splice variants of the KRAS gene18. Here, 
‘RAS’ will be used to refer generally to all isoforms. RAS are guanine nucleotide-binding 
proteins19,20 that cycle between active and inactive conformations conferred by GTP and 
GDP binding, respectively21,22.  
RAS regulators and effectors 
RAS proteins function as transducers of mitogenic signaling that link cell surface 
receptors to intracellular effector pathways (Figure 1). External growth factors induce 
cell proliferation by binding to receptor tyrosine kinases (RTKs) at the cell surface. 
Signal transduction between RTKs and RAS is mediated by cytosolic adaptor proteins, 
such as GRB2, CRKL, and IRS1. This RTK-adaptor protein-GEF interaction promotes 
RAS activation by recruiting the normally cytosolic guanine exchange factors (GEFs) to 
the plasma membrane where RAS is located18,23,24. 
Under physiologic conditions, the transition between RAS GTP- and GDP-bound 
states is regulated by GEFs and GTPase-activating proteins (GAPs). GEFs accelerate 
the release of GDP from RAS, enabling the more abundant GTP to bind in its place. On 
the other hand, GAPs accelerate RAS GTPase activity over 200-fold18. The most 
common oncogenic RAS mutations abrogate its interaction with GAPs25,26 and reduce 
!6!
intrinsic RAS GTPase activity ~10-fold, leading to the accumulation of active GTP-
bound RAS. 
Active, GTP-bound RAS interacts with numerous downstream effectors to 
activate signaling pathways important for cell growth and survival18,23,24. The three major 
effectors of oncogenic RAS signaling are RAF, PI3K, and RALGDS (Figure 1). Several 
other RAS effectors, such as the RAC-GEF TIAM1, PLC!, and pro-apoptotic RASSF 
family members have been identified, but their functions are not as well studied. 
The relative contribution of different RAS effector arms to RAS signaling is still 
unclear. Genetic suppression of individual effector pathways was shown to be sufficient 
to prevent RAS-mediated transformation in different model systems27-31. In certain 
contexts, signaling through a specific effector pathway is sufficient to induce cell 
transformation. For example, in a mouse model of pancreatic cancer, active BRAF, but 
not PIK3CA, was sufficient to induce tumorigenesis29. Contrastingly, in immortalized 
mouse cells, RAF activation induced transformation whereas RALGDS and PI3K 
activation did not32. Yet, in immortalized human cells, activation of RALGDS, but not 
RAF or PI3K, induced cell transformation32. Together, these findings demonstrate that 
the relative importance of each RAS effector arm is context-specific. 
RAS mutations in cancer  
RAS is the most frequently mutated oncogene in human cancers22,33.  RAS mutations 
occur in nearly all pancreatic cancers, ~50% of colorectal cancers, and ~30% of lung 
cancers33 (Table 1). The involvement of RAS signaling in cancer is evident not only by 
the high incidence of RAS mutations, but also by the high frequency of mutations in 
RAS regulators (such as RTKs and NF1) and RAS effectors (such as members of the 
MAPK and PI3K pathways)34,35.  
Over 95% of oncogenic RAS mutations involve point mutations in codons 12, 13, 
or 61 (analysis of the Catalog of Somatic Mutations in Cancer (COSMIC) database36). 
These G12, G13, or Q61 mutations decrease RAS intrinsic GTPase activity, reduce 
GAP binding affinity, and abrogate the ability of GAPs to stimulate RAS GTPase 
activity37. This causes RAS to accumulate in the active GTP-bound state, constitutively 
activating downstream effectors even in the absence of extracellular stimuli.  
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Oncogene addiction 
Cancer cells harboring mutationally activated oncogenes are frequently dependent on 
continued signaling from the activated signaling pathways. This phenomenon, termed 
“oncogene addiction,” provides a therapeutic opportunity because it renders cancer 
cells sensitive to drugs targeting these pathways. Of note, there is often a greater 
dependency on the oncogenic gene in cancer cells than in normal cells, conferring a 
large therapeutic window38,39. Targeting oncogene addiction has been successful in 
chronic myelogenous leukemia with the BCR-ABL fusion oncogene treated with ABL 
kinase inhibitors, in EGFR-mutant lung cancer with EGFR inhibitors, and in BRAF-
mutant melanoma with BRAF inhibitors40,41.  
RAS-mutant cells are dependent on continued RAS signaling for sustained 
survival/proliferation. An analysis of KRAS-mutant cell lines suggested that there is a 
spectrum of dependency42. However, the majority of human cancer cell lines3,42-44 and 
tumors from genetically engineered mouse models (GEMMs) harboring a mutant RAS 
allele demonstrate RAS addiction45-51. Indeed, removing KRAS from established tumors 
in mouse models results in dramatic tumor regression46,48,50. As the majority of RAS-
mutant cancers are addicted to RAS, there has been much interest in inhibiting RAS for 
cancer therapy.  
Strategies to target mutant RAS for cancer therapy 
Several approaches have been taken to therapeutically target RAS-mutant cancers, 
including: (1) inhibiting upstream RAS activators, (2) directly inhibiting RAS, (3) 
preventing RAS from associating with the plasma membrane, (4) inhibiting RAS effector 
pathways, and (5) inhibiting tumor-specific vulnerabilities that are induced by the 
oncogenic state (non-oncogene addictions or synthetic lethal interactions)52 (Figure 2). 
Inhibiting upstream RAS activators 
Inhibiting upstream RTKs could be effective in treating RAS-mutant cancers because 
these cells produce autocrine growth factors, such as EGF53. Indeed, an in vivo study 
demonstrated that autocrine EGFR activation is important for tumorigenesis in cancers 
driven by active SOS, which activates RAS54. However, subsequent clinical studies 
indicated that KRAS mutations predict insensitivity to EGFR inhibitor therapy, and RAS 
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mutation is currently an exclusionary criterion for EGFR inhibitor treatment for colorectal 
cancer55,56. Similarly, patients with RAS-mutant NSCLC are likely insensitive to EGFR 
inhibitor therapy57-61. 
Direct RAS inhibition 
As the majority of RAS-mutant cancers are addicted to RAS, there has been much 
interest in developing RAS inhibitors. Unfortunately RAS has proven difficult to target. 
RAS has a picomolar affinity for GTP/GDP, and the millimolar concentration of guanine 
nucleotides in the cytosol makes it unlikely that a competitive inhibitory nucleotide 
analogue will be developed62. Additionally, RAS activation and signaling is mediated by 
transient protein-protein interactions which are difficult to target via small molecules63. 
Despite these challenges, several groups have identified compounds that bind to RAS 
noncovalently and either abrogate RAS-RAF interaction64-69 or inhibit nucleotide 
exchange70-75. However, these early-stage compounds have low RAS-binding affinity 
and potency, and will have to be improved before clinical application. More recently, 
covalent inhibitors targeting KRASG12C have been developed76,77. These mutation-
specific electrophilic compounds irreversibly bind to the reactive cysteine in KRASG12C, 
blocking KRAS nucleotide exchange76,77. While KRASG12C mutations arise in ~15% of 
lung adenocarcinomas78, it occurs infrequently in other cancer types. It is possible that 
other compounds could be identified that specifically target RASG12D and RASG13D, but it 
will likely be difficult to selectively target other common RAS mutations due to their less 
reactive side chains. While the advances in efforts to directly target oncogenic RAS are 
encouraging, these approaches have yet to produce clinically usable agents.  
Targeting RAS post-translational modifications 
Another approach to inhibiting RAS is to target its post-translational modifications, which 
are necessary for RAS membrane association and biological activity79. RAS 
farnesylation by farnesyltransferase (FTase) is the first, irreversible, and rate-limiting 
step of the RAS post-translational modifications that increase RAS hydrophobicity and 
enable membrane association. Unfortunately, these FTIs did not demonstrate significant 
clinical benefit in patients, likely because KRAS4B and NRAS can be alternatively 
prenylated by geranylgeranyltransferase (GGTase) in the context of FTI treatment80-83; 
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this addition of a geranylgeranyl modification in place of farnesyl enables KRAS4B and 
NRAS to remain fully functional.  
Inhibiting RAS effector pathways 
Given that targeting RAS proteins or RAS modifier proteins directly has proven difficult, 
efforts have shifted towards alternative ways of selectively targeting RAS-mutant cells, 
such as inhibiting RAS effector pathways. While many RAS effector families have been 
identified, the RAF serine/threonine kinases (ARAF, BRAF, and CRAF) are thought to 
play a key role in RAS-mediated oncogenesis28,29. RAF activates the MEK1/MEK2 
kinases, for which the only known substrates are the ERK1/ERK2 kinases. However, 
because the MAPK signaling pathway involves multiple feed-forward and feedback 
mechanisms that dynamically modulate ERK activity, pharmacological inhibition of the 
MAPK pathway at the level of RAF and MEK have not demonstrated equivalent 
outcomes33,84,85. 
The ATP-competitive RAF inhibitors vemurafenib and dabrafenib have been 
approved for treatment of BRAF-mutant melanoma86,87. However, in NRAS-mutant 
melanoma, treatment with these first-generation BRAF inhibitors paradoxically activates 
the MAPK pathway through induction of RAF dimerization and consequent CRAF 
activation88-91. A second generation of ‘paradox-breaking’ BRAF inhibitors that do not 
promote RAF dimerizaton92 or pan-RAF inhibitors that inhibit all three RAF proteins93 
have been generated and may have improved efficacy in treating RAS-mutant cancers. 
Several MEK inhibitors are currently being tested in clinical trials for RAS-mutant 
pancreatic cancer, colorectal cancer, lung cancer, and melanoma. While MEKi has 
been successful in treating BRAF-mutant melanoma87,94, success has been limited in 
RAS-mutant NSCLC95-97, pancreatic cancer96, and melanoma98. A major mode of 
intrinsic or acquired resistance to MEK inhibitor monotherapy in RAS-mutant cancers is 
the reactivation of the RTK-RAS-MAPK pathway84. It was thought that ERK inhibition 
would overcome this mode of resistance. Unexpectedly, ERK inhibition was found to 
alleviate feedback inhibition of RAF, resulting in enhanced MEK activation99. Combined 
inhibition of RAF, MEK, and ERK may be necessary for more effective MAPKi, though 
overlapping toxicities could be limiting in patients. 
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The p110 catalytic subunits ("- #- and $-subunits) of class I PI3Ks are also 
important effectors of oncogenic RAS27,100,101. A Kras-driven mouse model of lung 
cancer suggested that PI3K signaling was essential for tumorigenesis and tumor 
maintenance102. However, small molecule inhibition of the PI3K pathway in a mouse 
model of lung cancer had little effect on Kras-driven tumor growth103, and subsequent in 
vitro studies suggested that oncogenic RAS confers resistance to PI3K inhibition104. It is 
unclear whether RAS-mutant cancers demonstrate greater dependence on PI3K 
signaling than cells driven by other oncogenes105, and several inhibitors of the PI3K-
AKT-mTOR signaling pathway are currently under clinical evaluation in RAS-mutant 
cancers.  
Oncogenic RAS signals through multiple signaling pathways, and it is possible 
that inhibition of a single effector arm will not be sufficient to induce tumor regression. In 
pre-clinical studies, combined MAPK and PI3K inhibition effectively induced regression 
of KRAS-mutant tumors103. There are several clinical trials assessing the efficacy of 
combined MAPK (MEK or ERK) and PI3K pathway (PI3K, AKT, or mTOR) inhibition in 
RAS-mutant cancers. The results of most of these trials are not yet available. However, 
while this dual-targeting strategy has the potential of being more effective than inhibition 
of either pathway alone, there may not be a wide enough therapeutic window to 
effectively suppress both pathways in human cancers106. In a recent trial that combined 
MK-2206 (AKT inhibitor) with selumetinib (MEK inhibitor), no patient achieved over 70% 
inhibition of both targets at the maximum tolerated drug dose107. 
In summary, while RAS effector inhibition is a promising strategy to target 
oncogenic RAS, several challenges endure. Inhibition of effector pathways are 
complicated by compensatory feedback mechanisms, which necessitate inhibition at 
multiple levels of the pathway. In addition, as several effectors pathways are important 
in oncogenic RAS signaling, concurrent inhibition of multiple pathways may be 
important. However, while combination inhibition of more than one effector pathway 
(such as RAF and PI3K) may be more effective in inducing tumor regression, the 
resulting increase in toxicity to normal cells may reduce the therapeutic window. 
Nevertheless, it remains possible that combined inhibition of different nodes of these 
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effector pathways (RAF, MEK, or ERK and PI3K, AKT, or mTOR) will yield different 
toxicities, with greater therapeutic windows in specific combination strategies.  
Synthetic lethality 
Synthetic lethal interactions for cancer therapy 
A synthetic lethal interaction (also known as induced essentiality, non-oncogene 
addiction, or co-dependency) refers to a genetic principle in which the combination of 
two genetic perturbations is lethal, whereas each individually is not38,39,108 (Figure 3). 
The concept of synthetic lethality emerged from genetic studies in model 
organisms109,110. Genotype-selective synthetic lethality is based on the concept that 
genetic alterations in cancer cells confer vulnerabilities that can be therapeutically 
targeted. Such vulnerabilities may be secondary to the inability to respond appropriately 
to a specific signal (such as DNA damage or cell cycle arrest) or the inability to maintain 
cellular homeostasis. It was first proposed over 20 years ago that synthetic lethal 
interactions could be used to identify new anticancer drug targets111. 
There are several theoretical benefits to a therapeutic strategy based on synthetic 
lethal interactions. If the targeted synthetic lethal interaction is selective for a cancer-
specific mutation, this mutation could be used as a biomarker to stratify patients for 
treatment. In addition, targeting a synthetic lethal interaction should provide a large 
therapeutic window, as only tumor cells that harbor the mutation should be sensitive.  
Lastly, the synthetic lethal strategy enables indirect targeting of “undruggable” mutations 
(such as loss of tumor suppressors and RAS) through the identification of an alternative 
synthetic lethal target.  
Exploiting synthetic lethal interactions may provide opportunities for rational drug 
development to treat RAS mutant malignancies. Breast and ovarian cancers with 
mutations in the tumor suppressor genes BRCA1 or BRCA2 are a paradigm for 
exploiting genotype-selective synthetic lethal interactions in targeted cancer 
therapy112,113. These tumors are dependent on the DNA repair enzyme PARP1 and 
respond to treatment with PARP inhibitors114. An attractive strategy for targeted drug 
development for RAS-mutant cancers involves identifying signaling pathways that 
become essential for cancer cell survival in the context of oncogenic RAS signaling.   
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Screening approaches to identify synthetic lethal interactions  
Screening approaches to identify clinically relevant synthetic lethal interactions 
face several hurdles115,116: (1) systematic identification of synthetic lethal interactions 
requires interrogation of large numbers of gene-pair combinations; (2) synthetic lethal 
interactions result in lethality, making mutant recovery and identification challenging; 
and (3) many synthetic lethal interactions are context-dependent, and may not be 
observed in all genetic backgrounds or cellular conditions. These challenges can be 
partly addressed through the use of high-throughput screening approaches. 
Two commonly used tools for genetic interrogation in human cells are RNA 
interference (RNAi) and CRISPR/Cas9. RNAi takes advantage of a conserved 
endogenous pathway that regulates gene expression via small RNAs117,118. 
Endogenous RNAi machinery can be appropriated by introducing synthetic small RNAs 
into cells. The introduced short interfering RNA (siRNA) or short hairpin RNA (shRNA) is 
loaded into the RNA-induced silencing complex (RISC), which in turn promotes the 
degradation of complementary target mRNA118,119.  
The CRISPR/Cas9 genome editing technique uses a guide RNA (gRNA) that 
targets the Cas9 endonuclease to specific sequences in the genome, and Cas9 
introduces a blunt-ended double-strand break (DSB). Repair can occur through the 
homologous recombination repair pathway or end-joining pathways such as non-
homologous end-joining (NHEJ) and alternative end-joining (AltEJ). The end-joining 
pathways are error-prone, and typically result in small insertions and/or deletions 
(indels). Indels are selected for in CRISPR screens, as error-free repair re-establishes 
the wildtype sequence, which is targeted again by the gRNA-guided Cas9. Indels in the 
gene can result in either a frameshift mutation that generates knockout through protein 
truncation or mRNA nonsense-mediated decay, or an in-frame mutation that may have 
a phenotypic effect depending on the structural or functional importance of the altered 
region120,121. 
Recent advances in RNAi and CRISPR technology have enabled massively 
parallel screens for synthetic lethal interactions in human cells. These screens are 
typically performed on either pairs of isogenic cell lines that differ only on the status of 
the gene of interest (Figure 4Ai), or a panel of genetically diverse cell lines that are split 
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into two groups depending on the status of the gene of interest (Figure 4Aii). Large-
scale perturbation of the expression of individual genes can be achieved using libraries 
of siRNAs, shRNAs, or gRNAs for CRISPR/Cas9 genome editing115,122. These reagents 
can be applied in an arrayed format (Figure 4B), in which the effect of each siRNA or 
shRNA is analyzed in individual wells, or in a pooled format, in which shRNA or gRNA 
vectors are combined in a pool and the change in relative abundance of individual 
shRNAs or gRNAs in the population is quantified (Figure 4C). A major advantage of the 
pooled screening approach is that large collections of shRNAs or gRNAs can be 
efficiently interrogated.  
RNAi-based targeted gene suppression provided the first opportunity to perform 
scalable genetic screens in human cells10,123-125. These systematic synthetic lethality 
screens have contributed much knowledge to human functional genomics. However, the 
lack of overlap in findings among independent RNAi screens have raised concern 
regarding RNAi reagent specificity116. More recently, large scale CRISPR/Cas9 screens 
have proven to be a powerful method to identify gene dependencies14.     
RNAi and CRISPR/Cas9 based screens have different technical and methodical 
advantages126. The major differences between the two technologies are in kinetics, 
penetrance, nature of phenotype, and specificity. (1) RNAi-mediated attenuation of gene 
expression is rapid, typically achieved in a matter of 1-2 days. Conversely, the 
CRISPR/Cas9 system usually requires at least a week to achieve maximum gene 
knockout120. (2) RNAi-mediated gene depletion is highly penetrant, with fairly uniform 
effects across individual cells. Contrastingly, to achieve complete gene knockout with 
the CRISPR/Cas9 system, every functional copy of the target gene must be disrupted; 
however, editing efficiencies of Cas9-expressing cells vary and can be below 
50%120,121,127,128, suggesting that many cells have incomplete gene knockout. Moreover, 
approximately 1/3 of indels are expected to be in-frame, and may not disrupt the ORF. 
Individual cells within a population may express the same gRNA, but acquire different 
mutations in the targeted gene, leading to phenotypic heterogeneity that contribute 
noise to large-scale screens126,129. (3) RNAi approaches typically result in incomplete 
knockdown phenotypes; for applications such as drug target discovery, phenotypic 
hypomorphs achieved by RNAi may better mimic the effect of chemical inhibition during 
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therapeutic application. CRISPR/Cas9 can achieve full genetic knockout, which may 
demonstrate a stronger phenotype and unveil additional genetic interactions. (4) Lastly, 
a major disadvantage of RNAi based approached is lack of specificity due to off-target 
effects, in which siRNAs can silence non-target mRNAs with limited sequence 
complementarity, often through interactions with the 3’-UTR130-132. The minimal overlap 
reported among independent RNAi screens have raised concern over the ability of RNAi 
to annotate gene function133. The CRISPR/Cas9 system is thought to be highly 
specific129, though off-target effects of the CRISPR/Cas9 system are likely not yet fully 
appreciated. Notably, genome editing by the CRISPR/Cas9 system has toxic effects, 
and in the setting of genome-scale screens in aneuploid cancer cells may result in the 
identification of false positive gene dependencies15,134.  
Challenges in screening for synthetic lethal interactions 
For large scale RNAI and CRISPR/Cas9 screens for synthetic lethal interactions, 
the two greatest remaining challenges are in reagent specificity and context 
dependence. For both RNAi and CRISPR/Cas9 screens, the efficiency of gene 
inactivation varies among individual shRNAs or gRNAs targeting the same gene. In 
addition, off-target effects associated with specific sequences contribute to false positive 
and false negative findings. Extensive efforts have been made to improve the specificity 
of RNAi libraries. RNAi design principles have emerged to increase on-target 
robustness and reduce off-target effects130,132,135,136, and library generation has 
improved through the incorporation of bioinformatics algorithms135,137,138. In addition, the 
analysis of large-scale RNAi screens have emphasized the importance of reducing false 
positives by observing consistent phenotypes in multiple RNAi reagents that target the 
same gene3,11,125,139. The CRISPR/Cas9 system was more recently discovered, and 
efforts are ongoing to improve on-target robustness and to define off-target effects129. 
However, early discoveries have been incorporated into the design of new gRNA 
libraries140-143. Loss-of-function screens for essential genes using these improved gRNA 
libraries have uncovered many common as well as cell line-specific fitness 
genes14,15,127,134 Ultimately, using the orthogonal RNAi and CRISPR/Cas9 systems in 
parallel will facilitate the identification of high-confidence synthetic lethal interactions. 
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An enduring challenge to identifying reproducible synthetic lethal interactions is 
context-dependence. Cell intrinsic (such as genetic background) and cell extrinsic (such 
as microenvironment) factors can modify synthetic lethal interactions. In yeast, it has 
been shown that certain genetic interactions are revealed only with the disruption of 
three or more genes144. This suggests that the genetic background of a cell line (such 
as loss of a tumor suppressor gene and nearby genes, oncogene activation, or even 
passenger mutations) could uncover or suppress synthetic lethal interactions. A major 
complication in screening for synthetic lethal interactions in isogenic cell lines is that the 
interactions identified may be context-dependent, occurring only in combination with 
other mutations or in a specific cell type or lineage (Figure 4Ai). Hence, a synthetic 
lethal interaction identified in any given cell pair may not be broadly valid. Issues of 
context dependency can be overcome by performing genetic screens in panels of 
diverse cell lines that are split during analysis based on the status of the gene of interest 
(Figure 4Aii,C). This thorough approach enables the identification of genes that are 
universally lethal in cells of diverse genotypes and lineages that harbor a specific 
mutation, circumventing the problem of context-dependence. However, this approach 
requires screening large numbers of cell lines, and could preclude the identification of 
strong synthetic lethal interactions that would be of clinical interest, but are conditional 
on specific genetic contexts.  
Genotype-selective synthetic lethal interactions with oncogenic RAS 
Several systematic genetic screens have been performed in human cancer cell 
lines to identify synthetic lethal interactions with mutant RAS. These studies have 
employed different screening modalities (cell line selection, time frame, pooled versus 
arrayed screening) and reagents (siRNA, shRNA, or CRISPR/Cas9)14,116,122,145. Screens 
were typically performed with pairs of isogenic cell lines, or with a panel of cancer cell 
lines that differ in RAS mutation status. These screens have confirmed that many 
KRAS-mutant cell lines are addicted to RAS, and identified many genes that may be 
synthetic lethal with oncogenic RAS (Table 2). These genes are involved in diverse 
processes, including cell cycle (BIRK5, PLK1, and APC/C), cell survival (BCL2L1 and 
WT1), transcription (GATA2 and SNAIL1), and parallel pro-proliferative pathways (TAK1 
and TBK1) (Table 2). 
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Thus far, none of the proposed synthetic lethal interactors have been able to 
discriminate between RAS-mutant and RAS-wildtype cells as well as KRAS itself145. In 
addition, there has been a striking lack of overlap in RAS synthetic lethal genes 
identified from different screens. The only genes to score across multiple screens have 
been proteasome complex members3,4,146,147. Oncogenic RAS has been reported to 
increase rates of protein synthesis, which may render cells more dependent on the 
proteasomal degradation of mutated or misfolded proteins148. However, it remains 
unclear whether RAS mutation status predicts response to proteasome inhibitor therapy 
in the clinic149.  
The first generation of RAS synthetic lethal screens have uncovered interesting 
biology in RAS-mutant cancers. However, the lack of overlap in identified synthetic 
lethal interactors with oncogenic RAS have raised concerns about the applicability of 
these findings116. There are multiple possible explanations for the low overlap across 
different screens. Studies have employed different reagents (siRNA or shRNA), 
screening modalities (time frame, pooled versus arrayed, and in vitro versus in vivo 
screening), and contexts (cell lineage, isogenic cell lines versus cell line panel)33,145. 
Each of these factors has unique limitations and likely contributes to false-negative and 
false-positive rates. It is likely that many synthetic lethal partners of oncogenic KRAS 
remain unidentified.  
While the first-generation RAS synthetic lethal screens have numerous limitations, 
they have led to several interesting targets, including TBK1 and WT1, which continue to 
be the focus of ongoing investigation3,5. Notably, TBK1 shows promise as a novel 
therapeutic target for KRAS-driven malignancies. Preclinical studies using a small 
molecule inhibitor of TBK1 achieved clear therapeutic responses in Kras-mutant 
GEMMs9. Additionally, studying TBK1 has led to the discovery of a novel effector 
pathway of oncogenic RAS, in which TBK1 promotes RAS-driven tumorigenesis by 
regulating an autocrine cytokine circuit. Such data support the idea that synthetic lethal 
genetic interactions can identify valuable therapeutic targets and broaden our 
understanding of critical mediators of oncogenic RAS, motivating our interest in 
identifying further novel candidates. Improvements in genome-scale screening 
technology, such as improved RNAi libraries and CRISPR/Cas9 knockout libraries, and 
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the use of expanded collections of cancer cell lines are promising for the discovery of 
novel synthetic lethal targets.  
Drug-conditional synthetic lethal interactions 
Single-agent targeted therapies have achieved impressive clinical responses in a 
variety of oncogene-addicted cancers87,150-154. However, the rapid development of drug 
resistance limits therapeutic efficacy, and single-agent targeted therapies are rarely 
curative155,156. The highly interconnected nature of signaling pathways limits the benefits 
of inhibiting a single signaling pathway156-158. Feedback mechanisms among signaling 
pathways enable cells to maintain pathway activity despite the presence of a small 
molecule inhibitor. A better understanding of the alternative pathways that become 
essential to maintain viability when a major signaling pathway is pharmacologically 
inhibited (termed ‘drug-conditional synthetic lethal interactions’) would facilitate the 
design of rational combination therapeutic regimens (Figure 5). For example, a drug-
conditional synthetic lethal interaction was recently identified in BRAF-mutant colon 
cancers: shRNA screens demonstrated that depletion of EGFR is synthetic lethal with 
small molecule BRAF inhibition, suggesting a that combined BRAF and EGFR inhibition 
could be of clinical utility159,160. Several clinical trials assessing the clinical utility of this 
combination of inhibitors are currently ongoing, and early phase clinical trials have 
reported promising results161. This suggests that pharmacologically targeting drug-
conditional synthetic lethal interactions may increase the efficacy of existing therapeutic 
agents. 
Given that RAS has proven difficult to target directly, therapeutic efforts in RAS-
mutant cancers have focused on inhibiting downstream RAS effector pathways, such as 
the MAPK and PI3K pathways. As discussed previously, the strategy of inhibiting 
downstream RAS effectors (such as the MAPK and PI3K pathways) has had limited 
therapeutic efficacy. There has been much interest in conducting drug-conditional 
synthetic lethality screens to identify enhancers of MEK inhibition in KRAS-mutant 
tumors. shRNA screens have identified BCL-XL162 and HER3163 as synthetic lethal 
interactors with MEKi in KRAS-mutant cancers . Clinical trials combining MEK inhibitors 
with pan-HER inhibitors or BCL-XL inhibitors are currently in progress. Such data 
support the idea that drug-specific synthetic lethal interactions can be leveraged to 
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increase the cytotoxicity of existing therapies and deepen our understanding of 
oncogenic RAS signaling.  ! !
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Results 
Candidate synthetic lethal interactions with oncogenic KRAS  
We analyzed the data from Project Achilles v2.4, which consists of 216 cell lines 
screened with a genome scale shRNA library12, to identify synthetic lethal target genes 
with specific essentiality in KRAS-mutant cells (Figure 2-1). To reduce the likelihood of 
identifying lineage-specific rather than KRAS-mutant-specific essential genes, we 
focused our analyses on carcinoma cell lines (133 of 216 cell lines).  
To address potential off-target effects, we used a computational method 
developed in our laboratory, ATARiS (Analytic Technique for Assessment of RNAi by 
Similarity) to generate a gene-level essentiality score based on RNAi reagents whose 
phenotypic effects are most likely related to suppression of their intended targets139. 
The underlying assumption is that shRNAs designed to interrogate the same gene 
should have similar on-target effects in addition to individual off-target effects from 
perturbation of unintended transcripts. Hence, the on-target effects of shRNAs targeting 
the same gene can be estimated by quantifying the similarity in the pattern of 
phenotypic effect across multiple cell lines. 
A two-class comparison was performed by classifying cell lines as KRAS-mutant 
(37 cell lines) or KRAS-WT (96 cell lines) using KRAS mutation status reported in the 
Broad-Novartis Cancer Cell Line Encyclopedia (CCLE) database164 and using a mutual 
information based metric12 to rank dependency data (shRNA- or gene- level) based on 
the degree of correlation with KRAS mutation status. In this analysis, KRAS itself was 
identified as the top candidate whose expression is selectively essential for the 
survival/proliferation of KRAS-mutant cells (Table 3). As KRAS depletion is known to 
induce cell death in KRAS-mutant cells (KRAS addiction), the identification of KRAS as 
a genetic dependency of KRAS-mutant cell lines serves as a positive control for this 
analysis. Aside from KRAS, 8 genes scored as significantly essential (FDR < 0.25) for 
the proliferation/survival of KRAS-mutant cells (Table 3). 
Prior studies indicate that a subset of KRAS-mutant cell lines are insensitive to 
KRAS depletion3,42. Conversely, while the majority of KRAS-WT cell lines are KRAS-
independent, some are sensitive to KRAS depletion. Indeed, we found that KRAS 
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mutation status did not always predict KRAS dependency (Figure 7). To identify genes 
whose expression is essential in cell lines that are both KRAS-mutant and KRAS 
dependent, two-class comparisons were performed in which cell lines were classified by 
(1) KRAS mutation status and sensitivity to KRAS depletion as measured by the KRAS 
ATARiS score139, a value that reflects the aggregate effects of 10 KRAS shRNAs 
screened in Project Achilles; or (2) KRAS mutation and sensitivity to KRAS depletion by 
shKRAS-1, a KRAS-targeting shRNA that effectively depletes KRAS expression at a 
protein level3 (Figure 8, Table 4). Two-class comparisons were performed on shRNA 
level and ATARiS (gene) level data (Figure 6). In all two-class comparisons, KRAS was 
identified as the most statistically significant candidate. In total, 59 candidate oncogenic 
KRAS co-dependencies were identified for further study (Table 5). 
 There is little overlap between the previously identified co-dependencies of 
oncogenic KRAS (Table 2) and candidates from this analysis (Table 5, highlighted in 
gray). Of the previously identified co-dependencies, only TAK142, WT15, CDK2 and 
CDK6165 score in any of the analyses. This could be attributable to a variety of factors: 
some of the previously identified genes may be cell line or lineage specific 
dependencies. Several candidates identified in these analyses were not screened in 
prior studies. Additionally, some of the previously identified candidates that were not 
identified as significant co-dependencies in these analyses (GATA2 and STK33) may 
have been false positives secondary to shRNA off-target effects11. Lastly, genes 
involved in autocrine pro-survival cytokine signaling pathways, such as TBK13, are 
unlikely to be identified from pooled screens such as Project Achilles due to 
compensatory cytokine signaling from neighboring cells. 
Off-target effects complicate the interpretation of RNAi screens 
In the two-class-comparison analysis in which cell lines were classified by KRAS 
mutation status, COG2 was the most statistically significant gene, and its depletion had 
the greatest magnitude of differential effect between KRAS-mutant and KRAS-WT cell 
lines, with the exception of KRAS itself. COG2 remained a significant candidate gene in 
the analyses in which cell lines were classified by KRAS mutation status and 
dependency (Table 5). Moreover, when the analogous analyses were performed on an 
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independently derived dataset166, in which genome-scale pooled shRNA screens were 
performed across 72 cancer cell lines (59 with known KRAS mutation status, including 
26 KRAS-mutant and 33 KRAS-WT), COG2 was again identified as a co-dependency of 
KRAS-mutant cell lines (Table 3 and 5). Hence, COG2 was prioritized for validation as 
a selective dependency of KRAS-mutant cells. 
All five COG2-targeting shRNAs screened in Project Achilles deplete COG2 
expression at the mRNA and protein level (Figure 9). The two shRNAs (shCOG2-4 and 
shCOG2-5) that best distinguished between KRAS-mutant and KRAS-WT cell lines in 
Project Achilles were selected to be assessed in a cell proliferation assay. One KRAS-
WT cell line (BXPC3) and three KRAS-mutant cell lines (HPAC, HPAFII, and YAPC) 
were infected with two shCOG2, two shKRAS, and two control shRNAs. In this initial 
assay, both KRAS-WT and KRAS-mutant cell lines appear sensitive to COG2 depletion 
(10A).  
The possible off-target effects of shCOG2 shRNAs were assessed in four ways: 
1) performing a rescue experiment; 2) assessing the effect of three additional COG2-
targeting shRNAs on cell viability; 3) evaluating sh911 seed-control shRNAs167 for 
individual shCOG2 shRNAs; and 4) using the CRISPR/Cas9 system to evaluate the 
effect of COG2 knockout. In the rescue experiment, a KRAS-mutant cell line (HPAC) 
was infected with either LacZ (control) or COG2 cDNA. Subsequently, COG2 
expression was suppressed using two shRNAs, one (shCOG2-6) of which targets the 
3’-untranslated region (UTR) of COG2 (Figure 11A). Overexpressing COG2 did not 
restore cell viability/proliferation (Figure 11B). However, it is possible that the 
exogenously expressed COG2 was not functionally active, as it contains a N-terminal 
V5 tag. 
COG2 was evaluated as a putative co-dependency of oncogenic KRAS by 
testing additional shCOG2 shRNAs tested in a cell proliferation assay. Three shCOG2 
shRNAs, which were not screened in Project Achilles and which effectively reduce 
COG2 expression were selected (Figure 12A). In two KRAS-mutant and two KRAS-WT 
cell lines, the effect of the two shCOG2 shRNAs that were screened in Project Achilles 
(shCOG2-5 and shCOG2-6) mirror the effects of the two shKRAS shRNAs (Figure 
12B). However, the effects of the three novel shCOG2 shRNAs (shCOG2-7, shCOG2-8, 
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and shCOG2-9) did not correlate with KRAS mutation or KRAS dependency (Figure 
12B). This suggested that COG2 might not be a true co-dependency of KRAS-mutant 
cells. 
C911 seed-control shRNAs167, in which bases 9 through 11 of the shRNA 
targeting sequence are replaced with their complement (Figure 13A), were used to 
assess off-target effects of two shKRAS shRNAs and the two shCOG2 shRNAs that 
were found to correlate with KRAS dependency. These shRNAs were evaluated in a 
cell proliferation assay in one KRAS-WT cell line (NCIH1437) and two KRAS-mutant cell 
lines (PANC0203 and YAPC) (Figure 13B). Results indicate that one of the shRNAs 
targeting KRAS, shKRAS-2, has off-target effects that decrease cell viability (Figure 
13B, both C911 shKRAS-2 and shKRAS-2 decrease the viability of KRAS-WT 
NCIH1437). shKRAS-1, on the other hand, does not demonstrate such off-target effects 
(Figure 13B, neither C911 shKRAS-1 nor shKRAS-1 decrease the viability of KRAS-
WT NCIH1437). shCOG2-4 and shCOG2-5 do not appear to have strong off-target 
effects that decrease cell viability (cell viability is decreased by both shCOG2 shRNAs 
but not the C911 seed-control shRNAs, Figure 13B). As COG2 depletion decreased 
viability of all cell lines assessed, one of which was KRAS-WT and KRAS-independent 
(NCIH1437), COG2 is not a selective co-dependency of KRAS-mutant or KRAS-
dependent cell lines.   
The CRISPR/Cas9 gene knockout system120 provides an orthogonal method to 
assess the effect of COG2 loss. We assessed the effect of COG2 (gCOG2) or KRAS 
(gKRAS) knockout in a KRAS-WT cell line (NCIH1437) and a KRAS-mutant cell line 
(YAPC) in a crystal violet cell proliferation assay. We found that KRAS knockout 
reduced viability in KRAS-mutant cells, but had no effect in NCIH1437. COG2 knockout 
did not affect viability in KRAS-WT or KRAS-mutant cells (Figure 14).  
In summary, our experiments demonstrate that COG2 suppression result in no 
differences in viability between KRAS-WT and KRAS-mutant cells, indicating that COG2 
is not a co-dependency of KRAS-mutant cells. Off-target effects can be a significant 
source of false-positives in shRNA-based experiments. Additionally, the KRAS-mutant 
cell lines screened in Project Achilles are predominantly of pancreatic, lung, and colon 
lineages; the candidate genes identified from the two-class comparisons described 
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above (Table 5) could be confounded by lineage-specific (rather than KRAS-mutant-
specific) dependencies. The fact that COG2, the highest priority candidate from the 
analyses described above, failed to validate as a co-dependency of KRAS-mutant cells 
highlights the importance of incorporating additional filters to prioritize candidate genes 
and the use of efficient and unambiguous assays to validate candidate co-
dependencies of oncogenic KRAS.  
Prioritized candidate co-dependencies of oncogenic KRAS 
We have considered three approaches to refining the list of candidate synthetic lethal 
interactors with oncogenic KRAS identified through analyzing Project Achilles shRNA 
screens (Table 5): (1) prioritize genes that are more highly expressed in KRAS-mutant 
cells; (2) analyze genome scale CRISPR/Cas9 knockout screens and prioritize genes 
that are confirmed to be selectively essential in KRAS-mutant cells using this orthogonal 
approach to genetic perturbation; and (3) exclude candidate genes that likely score 
secondary to off-target effects by computationally estimating the seed effects of the 
shRNAs used in the Project Achilles screens. 
 The list of the candidate genes (Table 5) can be refined by prioritizing genes that 
are more highly expressed in KRAS-mutant cells. This selection criterion assumes that 
genes that promote cell proliferation/survival selectively in the context of oncogenic 
KRAS are likely to be overexpressed in KRAS-mutant cells than in KRAS-WT cells. We 
analyzed RNA-sequencing data of cell lines in the Cancer Cell Line Encyclopedia 
(CCLE)164 to identify genes that were significantly upregulated in 130 KRAS-mutant 
carcinoma cell lines compared to 769 KRAS-WT carcinoma cell lines (t-test, FDR < 
0.05). Of the 59 candidate genes, 6 were overexpressed in KRAS-mutant cell lines 
(ABP1, BCL2L1, CXCL6, DOCK5, FERMT1, and NCOR2) (Figure 15A). Of note, not all 
genes that are selectively essential in KRAS-mutant cell lines are expected to be 
upregulated – indeed, KRAS itself is not significantly overexpressed in KRAS-mutant 
cells.  
As an orthogonal approach to identify KRAS synthetic lethal interactions, our 
laboratory has performed genome-scale CRISPR/Cas9 loss-of-function genetic 
screens. The screens have performed in 53 cancer cell lines (32 KRAS-mutant and 21 
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KRAS-WT). In this screen, candidate genes are knocked out through genome editing by 
the CRISPR/Cas9 system using the genome-scale CRISPR/Cas9 knockout version 2 
(GeCKOv2)168 or Avana141 library. Conceptually, this screen is analogous to the shRNA-
mediated Project Achilles screen described above (Figure 6). However, there are 
several advantages to a knockout (versus knockdown) approach. The CRISPR/Cas9 
system is a highly specific and efficient tool for genetic ablation, with greater 
consistency of effect among gRNAs targeting the same gene than is typically observed 
with shRNAs. This specificity likely improves the signal-to-noise ratio and decreases the 
false-positive rate of the screen. Additionally, CRISPR-mediated genome editing 
completely eliminates target gene expression, and may induce stronger phenotypes 
than shRNA-mediated gene suppression, which only partially depletes target genes. 
Lastly, shRNAs and gRNAs presumably have non-overlapping off-target effects, making 
data from the CRISPR/Cas9 screen useful for prioritizing the candidate co-
dependencies of oncogenic KRAS identified from the shRNA screens. 
We performed a two class comparison on the Project Achilles CRISPR/Cas9 
knockout v3.6.2 dataset to identify genes that were selectively essential in KRAS-
mutant carcinoma cell lines. We identified 360 significant (FDR < 0.25) candidate 
genes, but only 4 (ATP2B4, DOCK5, KRAS, and RAF1) overlapped with the 59 
candidates nominated from analyses of the Project Achilles shRNA dataset (Figure 
15B). KRAS and RAF1 (CRAF) were anticipated co-dependencies of KRAS-mutant 
cells. However, DOCK5 and ATP2B4 have not been implicated in RAS signaling, and 
are high-priority candidates for follow-up studies.  
 Lastly, DEMETER is an algorithm that models the effects produced by individual 
shRNA as a linear combination of gene-related effects and seed-related effects11. In the 
shRNA library used in project Achilles, each gene is targeted by ~6 shRNAs. Each of 
these shRNAs have “seedalogs,” which are shRNAs that share the same seed 
sequence (residues 1-8 at the 5’ end of the guide strand) but that are designed target 
different genes. Similar to ATARiS, DEMETER estimates the on-target effect of shRNAs 
targeting the same gene by quantifying the similarity in their phenotypic effects across 
multiple samples. DEMETER also quantifies the off-target “seed” effect of individual 
shRNAs by quantifying the similarity in its phenotypic effect across multiple samples to 
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the effect of its seedalogs. If the effect of a given shRNA across multiple cell lines 
appears to be more similar to its seedalogs than to other shRNAs targeting the same 
gene, the primary effect of this shRNA is likely off-target. We used DEMETER on the 
Project Achilles v2.4 dataset to quantify the on- and off-target effects of individual 
shRNAs. We found that only 14 of the 59 candidate genes were identified by at least 2 
shRNAs that had an estimated on-target effect of >50% (Figure 15C). These candidate 
genes are less likely to have been identified as a candidate co-dependency of KRAS-
mutant cells due to off-target shRNA effects.  
Potential dependency of KRAS-mutant cancer cells on DOCK5  
DOCK5 is a guanine exchange factor (GEF) that is known to activate RAC1, a 
member of the Rho GTPase family169. We selected DOCK5 for further study because it 
was more highly expressed in KRAS-mutant than KRAS-WT cell lines (Figures 15A 
and 16). Moreover, analyses of both Project Achilles shRNA and CRISPR/Cas9 screens 
identified DOCK5 as being specifically essential in KRAS-mutant cells (Figure 15B).  
 We assessed the effect of DOCK5 depletion in a KRAS-WT cell line (NCIH1437) 
and a KRAS-mutant cell line (PATU8902). We found that DOCK5 depletion reduced 
viability of KRAS-mutant cells, but had no effect on KRAS-WT cells (Figure 7A). 
Interestingly, we noticed that shRNAs targeting DOCK5 not only reduced DOCK5 
expression, but also reduced KRAS expression (Figure 7B). We generated C911 seed-
control shRNAs167 to assess the potential off-target effects of the DOCK5-targeting 
shRNAs. We found that both C911 shDOCK5-2 and shDOCK5-2 reduce KRAS 
expression, though only shDOCK5-2 reduces DOCK5 expression (Figure 18A-C). 
Notably, both C911 shDOCK5-2 and shDOCK5-2 reduce viability of KRAS-mutant cells, 
suggesting that shDOCK5-2 reduces viability of KRAS-mutant cells due to off-target 
suppression of KRAS expression rather than its suppression of DOCK5 expression 
(Figure 18D). In line with this hypothesis, a different DOCK5-targeting shRNA 
(shDOCK5-3) and its seed control (C911 DOCK5-3) do not reduce KRAS expression 
have no effect on cell viability (Figure 18).  
 To further assess the effect of DOCK5 loss on KRAS expression and cell 
viability, we reduced DOCK5 expression using two tools: siRNAs and CRISPR/Cas9. 
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We assessed the effect of siRNA-mediated DOCK5 depletion in two KRAS-mutant cell 
lines (HCT116 and PATU8902). We utilized a pool of four siRNA duplexes designed to 
target distinct sites within DOCK5 (Dharmacon SMARTpool). We found that siRNAs 
targeting DOCK5 effectively reduced DOCK5 expression without decreasing KRAS 
expression at the mRNA or protein level (Figure 19A-C). However, DOCK5 depletion 
had no effect on cell viability (Figure 19D).  
 Subsequently, we used the CRISPR/Cas9 system to knockout DOCK5 in the 
KRAS-mutant cell line PATU8902. We tested 4 gRNAs targeting DOCK5, and found 3 
that effectively knocked out DOCK5 as indicated by reduced DOCK5 mRNA expression 
(Figure 20A). We found that DOCK5 deletion had no effect on KRAS expression or on 
downstream MAPK or PI3K pathway activity (Figure 20B,C). In addition, we found that 
DOCK5 deletion had no effect on cell viability (Figure 20D,E). Overall, our findings 
suggest that DOCK5 does not regulate KRAS expression, and that DOCK5 depletion 
does not affect viability in KRAS-mutant cells.  
DOCK5 modifies sensitivity to MAPKi in RAS-mutant cancers 
Drug-conditional synthetic lethal interactions may be leveraged to increase the efficacy 
of existing therapeutic agents. As discussed above, one of the most promising methods 
of targeting RAS-mutant cancers is to inhibit downstream effector pathways, such as 
the MAPK pathway. Unfortunately, many RAS-mutant cancers demonstrate intrinsic or 
acquired resistance to MAPKi96,97. The development of genome-scale RNAi170 and 
CRISPR/Cas9141,168,171 libraries enable the systematic identification of loss-or-function 
events that increase drug sensitivity. These drug-conditional synthetic lethal interactions 
could inform the rational design of combined chemotherapy regimens. 
 Our laboratory has previously performed 6 genome-scale CRISPR/Cas9 screens 
to identify modifiers of sensitivity to MAPKi in 5 cancer cell lines harboring KRAS, 
NRAS, or BRAF mutations172,173 (Figure 21A). In PATU8902 (KRAS-mutant, pancreas) 
cells treated with the MEK inhibitor trametinib, 4 of the 6 gRNAs targeting DOCK5 
became strongly enriched; strikingly, out of ~200,000 screened gRNAs, there were 3 
gRNAs targeting DOCK5 among the 15 most enriched gRNAs (Figure 21B). This 
suggests that DOCK5 knockout might confer resistance to MAPKi. The major known 
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function of DOCK5 is to activate the small GTPase RAC1174,175. However, the majority 
of gRNAs targeting RAC1 were depleted in this screen, suggesting that RAC1 knockout 
sensitizes cells to MAPKi (Figure 21Bi).  
When we examined the sequences of the gDOCK5 gRNAs, we found that the 4 
DOCK5-targeting gRNAs that were enriched in the PATU8902 screen clustered around 
amino acids 31-56, which maps to the middle of the SH3 domain of DOCK5 (Figure 
21C). DOCK5 activity is thought to be autoinhibited through interactions between its N-
terminal SH3 domain and the C-terminal DHR2 domain176. In the process of gene 
editing, the CRISPR/Cas9 system may generate in-frame insertion/deletions or point 
mutations177, a property that has been capitalized on to rapidly generate diverse 
variants for gain-of-function screens178,179 Notably, an I32K point mutation in the SH3 
domain of the closely related protein DOCK1 abrogates autoinhibition and results in 
constitutively active DOCK1176. It is possible that the enriched DOCK5-targeting gRNAs 
introduced gain-of-function mutations in the SH3 domain of DOCK5 that abrogate its 
autoinhibition. Consistent with this vein of thought, a gRNA targeting MAP2K1 (MEK1) 
was the fourth most enriched gRNA in this screen (Figure 21Bii); as trametinib is a 
MEK1 inhibitor, this particular gRNA likely induced a gain-of-function mutation in MEK1.  
 We analyzed screening data172,173 from 4 other cell lines (RAS- or BRAF-mutant 
lung or pancreatic cancer cells) treated with MAPK pathway inhibitors (MEK inhibitor 
trametinib or BRAF inhibitor vemurafenib) to assess how gRNAs targeting DOCK5 and 
RAC1 modulated sensitivity. We found that in most cell lines, gRNAs targeting DOCK5 
and RAC1 were significantly depleted, suggesting that reduction in DOCK5-RAC1 
pathway activity increases sensitivity to MAPKi in RAS- and BRAF-mutant cells.   
 To determine whether DOCK5 knockout altered sensitivity to MEKi in PATU8902 
cells, we performed a competition assay to determine whether DOCK5 knockout altered 
sensitivity to MEKi. PATU8902 cells that were DOCK5-WT (gGFP) were mixed with 
PATU8902 cells that were DOCK5-KO (gDOCK5) in a 1:1 ratio, and the change in 
proportion of DOCK5-WT vs. DOCK5-KO cells was monitored over time. We found that 
DOCK5 deletion reduced cell proliferation/viability only when cells were exposed to the 
MEK inhibitor trametinib (Figure 22B). This suggests that loss of DOCK5 increases 
sensitivity to MEKi in RAS-mutant cells. 
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 Given our observation that DOCK5 deletion increases sensitivity to MAPKi in 
RAS- and BRAF-mutant cells, we hypothesized that DOCK5 deletion might perturb RAS 
effector pathways such as the MAPK or PI3K pathways. We found that DOCK5 deletion 
reduces PI3K pathway activity but has no effect on MAPK pathway activity (Figures 23, 
24).  !  
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Discussion 
Candidate synthetic lethal interactions with oncogenic KRAS 
Targeting genes that are selectively essential in the context of oncogenic RAS signaling 
is an attractive approach to targeted therapy for RAS-mutant cancers. We analyzed 
data from Project Achilles v2.4, in which a comprehensive genome-scale shRNA screen 
was performed across 216 human cancer cell lines, and identified 59 candidate genes 
that may be selectively essential in KRAS-mutant cancer cells. We found that the most 
statistically significant candidate gene, COG2, failed to validate and was likely identified 
as a consequence of shRNA off-target effects. Our experience with COG2 highlights the 
need to unambiguously determine whether a putative co-dependency identified from 
shRNA screening data scored due to on- or off-target shRNA effects. This can be 
achieved in a variety of ways, including (1) testing additional RNAi reagents, (2) using 
C911 seed-control shRNAs to evaluate off-target effects167, (3) performing a rescue 
experiment, and (4) utilizing the orthogonal CRISPR/Cas9 system to knockout120 or 
inhibit180 gene expression.  
We propose three ways to filter candidate genes in order to enrich for bona fide 
KRAS-mutant co-dependencies: (1) prioritize genes that are overexpressed in KRAS-
mutant cells (6 genes), (2) exclude genes that likely scored due to off-target seed 
effects as estimated using the recently developed bioinformatics algorithm DEMETER11 
(14 genes), and (3) prioritize genes that also scored in our analyses of Project Achilles 
v3.6.2, in which 53 cancer cell lines were screened using a genome scale 
CRISPR/Cas9 library (4 genes).  
It is increasingly appreciated that shRNA off-target effects confound the 
interpretation of RNAi-based screens.  For the majority of this work, we endeavor to 
minimize the identification of false positive candidates through using multiple shRNA 
constructs to target each gene and inferring on-target reagents by using the algorithm 
ATARiS139 to identify the shRNA constructs that have strongly concordant effects 
across cell lines. However, residual RNAi off-target effects persisted, and the most 
statistically significant gene (COG2) failed to validate experimentally.  
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Analysis of shRNA screening data across a panel of >500 cancer cell lines 
demonstrated that the viability phenotype across cell lines for pairs of shRNAs that 
share 7-mer seed sequences (which are responsible for the miRNA-like off-target 
effects) were significantly more correlated than that of shRNAs targeting the same 
gene11, highlighting the prevalence and robustness of miRNA-like seed effects. 
DEMETER11 is a recently developed analytical approach that takes advantage of the 
fact that both the on-target and seed-based effects of RNAi are sequence specific130,167. 
DEMETER deconvolutes the effects of each shRNA into a linear combination of the 
effects due to target gene depletion and the effects associated with the seed 
sequences, outperforming algorithms that are based solely on correlation (such as 
ATARiS, which was used to identify genes in this work) in identifying on-target 
biologically meaningful genetic dependencies11. Using DEMETER, we found that 14 of 
the 59 proposed candidate genes have at least 2 shRNAs with an estimated on-target 
effect >50%. These 14 genes are likely enriched for genuine co-dependencies of 
oncogenic KRAS, and are of high priority for further investigation. 
An alternative approach to address shRNA off-target effects is to use an 
orthogonal system, such as CRISPR-Cas9, and investigating genes that are identified 
from both screening approaches. Analysis of the Project Achilles shRNA and 
CRISPR/Cas9 screens identified 59 and 360 candidate synthetic lethal interactions with 
mutant KRAS, respectively, with only 4 genes identified in both. The low overlap 
between KRAS-mutant synthetic lethal candidate genes nominated from analyses of 
Project Achilles shRNA and CRISPR/Cas9 data is likely attributable to a combination of 
technical artifacts and biologic factors. 
As discussed previously, RNAi reagents are associated with off-target miRNA-
like seed effects. While the CRISPR/Cas9 system demonstrates high specificity in gene 
targeting129,177, off-target effects are likely not yet fully appreciated. Indeed, our 
laboratory and others have recently identified target gene-independent induction of cell-
cycle arrest mediated by Cas9 endonuclease activity, likely secondary to DNA 
damage15,134. shRNA or CRISPR/Cas9 off-target effects may result in the identification 
of false-positive candidates or the exclusion of bona fide candidates due to false-
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negative results, contributing to the low overlap in candidate genes nominated from 
analysis of the shRNA and CRISPR/Cas9 screens.  
Technical artifacts, such as reagent off-target effects or incomplete penetrance of 
CRISPR/Cas9-mediated gene knockout, limit the degree of saturation achieved in the 
shRNA and CRISPR/Cas9 screens. If a particular pathway or complex is essential in 
the context of a genetic alteration, genes encoding all the important components of that 
pathway or complex should be identified in a saturated synthetic lethal screen. In large-
scale screens for synthetic lethal genetic interactions in Saccharomyces cerevisiae, a 
microorganism in which high fidelity gene disruption is readily achieved181, the set of 
synthetic lethal interactions associated with a particular gene is typically enriched for all 
of the genes encoding the components of a functionally related pathway or complex182-
185. The paucity of relationships (such as pathway or complex membership) observed 
among the candidate synthetic lethal interactors with oncogenic KRAS nominated here 
suggests that our screens have not reached genetic saturation. 
In addition, several biologic factors contribute to the low overlap in candidate 
genes nominated from the shRNA and CRISPR/Cas9 screens. Certain candidates 
(such as cell essential genes) may only have a differential effect as hypomorphs, and 
would score only in the shRNA screen186. Conversely, genes with large functional 
reserve that are not effectively depleted in the shRNA-based screen may only score in 
the CRISPR-mediated screen. Moreover, the cell line panels used in the shRNA versus 
CRISPR/Cas9 screens differed in number (216 versus 53 cell lines) and proportion of 
particular cell lineages (such as lung, pancreas, or colorectal). As synthetic lethal 
interactions are highly context dependent, the differences in composition of cell line 
panels likely reduced the overlap in candidate genes identified from the shRNA and 
CRISPR/Cas9 screens.  
In both RNAi and CRISPR/Cas9 screens, KRAS depletion appears to be the 
most robust and consistent mode of reducing proliferation/viability of KRAS-mutant 
cancer cells. There may be no universal synthetic lethal interaction with mutant KRAS 
that has equivalent potency to targeting KRAS itself across the spectrum of KRAS-
mutant cancers. Nevertheless, while KRAS itself appears to be the strongest genetic 
dependency in KRAS-mutant cells, the identification of weaker but consistent co-
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dependencies across KRAS-mutant cancers could provide valuable insight into 
oncogenic KRAS signaling and function. It is likely that strong synthetic lethal 
interactions with mutant KRAS exist within specific combinations of tissue type and 
mutational background; these context-specific synthetic lethal interactors are attractive 
candidates for targeted therapy3,9. 
Overall, our findings suggest that screening large numbers of cell lines will be 
necessary for sufficient power to overcome the genetic heterogeneity of cancer cell 
lines to identify co-dependencies of KRAS-mutant cells that are widely applicable, and 
which may enhance our understanding of oncogenic KRAS signaling. Focusing 
screening efforts on specific cell lineages would reduce the number of cell lines 
required, and may unveil robust context-specific dependencies that are clinically 
valuable. The information derived from shRNA and CRISPR/Cas9 screens are 
complementary, and may identify non-overlapping co-dependencies for a variety of 
technical and biologic reasons. Secondary screens (such as an arrayed shRNA screen 
with appropriate C911 control shRNAs or a candidate mini-pool CRISPR/Cas9 screen) 
that enable head-to-head comparison of the union of candidate genes nominated by 
analyses of shRNA and CRISPR/Cas9 screens across large panels of cell lines could 
be an effective method of initial candidate gene validation and prioritization. 
DOCK5-RAC1 pathway in RAS-mutant cells 
Further exploration is warranted to determine if DOCK5 suppression is synthetic 
lethal to oncogenic KRAS 
We initially identified DOCK5, which is overexpressed in KRAS-mutant cells and scores 
in both Project Achilles shRNA and CRISPR/Cas9 screens, as a candidate co-
dependency of oncogenic KRAS. Our validation experiments suggested that DOCK5 
depletion is not synthetic lethal in the context of mutant RAS. However, this could be 
definitively concluded as there were weaknesses in our validation experiments: (1) the 
shDOCK5 shRNA that best distinguishes between KRAS-mutant and KRAS-wildtype 
cells has an off target effect in which it reduces KRAS expression.  However, the seed 
effects of other shDOCK5 shRNAs that selectively reduced viability of KRAS-mutant 
were not evaluated. (2) We used pooled siRNAs to deplete DOCK5 in KRAS-mutant 
!6P!
cells, and found no effect on cell viability despite ~50% reduction in DOCK5 mRNA 
expression. Given the transient effect of siRNA-mediated mRNA depletion, we 
assessed for differences in viability 4 days after siRNA transfection. The screens in 
Project Achilles are conducted over the course of 16 cell doublings (typically >20 days); 
this allows time for protein turnover and amplification of differences in proliferation rate. 
Although we reduced DOCK5 mRNA expression (protein level could not be assessed 
due to lack of DOCK5-specific antibody), residual DOCK5 protein may have 
compensated in the short term. Additionally, we used CellTiter-Glo, a luminescence 
based cell viability assay, to quantify cell number; in our experience, this reagent is not 
sufficiently sensitive to detect modest differences in cell number. (3) We found that 
CRISPR/Cas9-mediated DOCK5 knockout did not affect viability of KRAS-mutant cells. 
There are major limitations to our CRISPR/Cas9 experimental approach. In a population 
of cells expressing the same gRNA, there are some that achieve true knockout, others 
that express truncation or missense proteins, and yet others that suppress Cas9 or 
gRNA expression and evade genome editing. This heterogeneity may result in a mixture 
of individual phenotypes that cannot be detected at the population level. Additionally, we 
passage cells for at least 7 days after gRNA infection to allow time for gene editing120. 
However, if DOCK5 is required for viability, cells that achieve DOCK5 knockout will drop 
out, and over time we would select for a subpopulation of cells that have maintained 
DOCK5 expression or which acquired additional genetic alternations that rendered them 
resistant to DOCK5 deletion. An approach to definitively assess whether DOCK5 
depletion is synthetic lethal in the context of oncogenic RAS would be to use the 
CRISPR/Cas9 system to stably knockout DOCK5 in cells expressing exogenous 
DOCK5 (such as with a dox-inducible expression construct), and subsequently assess 
the effect of removing exogenous DOCK5. 
DOCK5 is an GEF that activates the small GTPase RAC1 by promoting the 
dissociation of GDP from RAC1, thereby facilitating GTP binding187,188. At least 20 GEFs 
are implicated in directly activating RAC1. These GEFs are subdivided into the Dbl or 
DOCK families, which differ in the domain mediating their GEF activity189. Intriguingly, 
since the experiments performed here (c. 2012-2014), a second generation 
CRISPR/Cas9 screen in a panel of acute myelogenous leukemia cells identified the 
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deletion of PREX1, a Dbl RAC1-GEF, to be synthetic lethal with mutant RAS14. 
Mechanistically, PREX1 expression was necessary to maintain MAPK pathway activity 
in RAS-mutant cells. Intriguingly, Wang et al. found that that PREX1 expression is 
restricted mainly to myeloid cells, and that in RAS-mutant non-myeloid hematopoietic 
cancers, a different Dbl-RAC-GEF, TIAM1, was selectively essential14. It is possible that 
RAC1 activity is essential in all RAS-mutant cells, and that RAC1 is activated by 
different RAC1-GEFs in different cell lineages (PREX1 in myeloid cells, TIAM1 in non-
myeloid hematopoietic cells, and DOCK5 in epithelial cells). Definitively determining 
whether DOCK5 expression is selectively essential in KRAS-mutant carcinomas will be 
critical to explore this hypothesis.  
DOCK5-RAC1 pathway modulates sensitivity to MAPKi in RAS-mutant cells 
Identifying genes whose suppression enhances drug sensitivity can enable rational 
design of combined therapy. We analyzed 6 genome-scale CRISPR/Cas9 screens to 
identify modifiers of sensitivity to MAPKi in RAS-mutant cells. We found that in 4 of the 
screens, gRNAs targeting DOCK5 were depleted, suggesting that DOCK5 deletion 
enhances sensitivity to small molecule MEK or BRAF inhibitors. The major known 
function of DOCK5 is to activate RAC1174,175. Notably, gRNAs targeting RAC1 were 
depleted in all 6 screens, suggesting that suppression of RAC1 signaling increases 
sensitivity to MAPKi.  
Interestingly, one of the screens (PATU8902 cells treated with the MEK inhibitor 
trametinib) showed strong enrichment of gRNAs targeting DOCK5. However, 
subsequent examination of the enriched gDOCK5 gRNAs showed that they target the 
autoinhibitory SH3 domain of DOCK5, where mutations might result in constitutively 
active DOCK5. We hypothesize that these gRNAs induced gain-of-function DOCK5 
mutations, and that this increase in DOCK5 activity conferred resistance to MEKi. 
Sequencing the DOCK5 locus from the genomic DNA of the end population of cells from 
this screen would allow us to profile the gRNA-induced mutations. 
We confirmed that in KRAS-mutant PATU8902 cells, DOCK5 deletion increases 
sensitivity to MEKi. An initial experiment suggested that deletion of DOCK5 reduces 
PI3K signaling as measured by p-AKT. The RAC1 and PI3K pathways are known to 
have significant crosstalk. For example, PI3K is thought to be directly activated by 
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RAC1. In turn, PIP3 (the lipid product of active PI3K), recruits and activates RAC1-
GEFs, further upregulating RAC1 activity190,191. This feed-forward circuitry between 
RAC1 and PI3K is necessary for the generation of a leading edge in migrating cells190, 
and may contribute to proliferation and survival of RAS-mutant cancer cells. In addition, 
prior studies suggest that RAC1 is able to is able to indirectly activate the MAPK 
pathway through PAK172,192. The next steps in determining if and how the DOCK5-RAC1 
pathway modulates sensitivity to MAPKi in RAS-mutant cells include: (1) suppress and 
overexpress DOCK5 and RAC1 in a panel of cell lines and evaluate the effect on cell 
viability, and (2) evaluate the effect of DOCK5 overexpression and suppression on 
levels of active (GTP-bound) RAC1 as well as MAPK and PI3K pathway activity.  
Oncogenic RAS activates several effector pathways, and concurrent inhibition of 
multiple pathways may be important. In pre-clinical studies, combined MAPK and PI3K 
inhibition effectively induced regression of KRAS-mutant tumors193. However, while this 
dual-targeting strategy has the potential of being more effective than inhibition of either 
pathway alone, there may not be a wide enough therapeutic window to effectively 
suppress both pathways in human cancers106. In a recent trial that combined MK-2206 
(AKT inhibitor) with selumetinib (MEK inhibitor), no patient achieved over 70% inhibition 
of both targets at the maximum tolerated drug dose107. Dock5-knockout mice 
demonstrate minor phenotypes, including high bone mass194, cataracts195, and reduced 
myoblast fusion196, suggesting that DOCK5 inhibition may have low toxicity. It will be 
interesting to evaluate whether C21194, a chemical inhibitor of DOCK, or small molecule 
inhibitors of the RAC1 pathway197 synergize with small molecule MAPK inhibitors to 
treat RAS-mutant cancers.  !  
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Conclusion 
In summary, we analyzed shRNA and CRISPR-Cas9 screening data across a large 
panel of cancer cell lines to nominate genes that are selectively essential in cells with 
mutant KRAS, highlighted experimental methods to unambiguously validate candidate 
genes, and identified DOCK5 as a modifier of sensitivity to MAPKi in RAS- or BRAF-
mutant cancers.  
 A major factor that has limited progress in RNAi screens for co-dependencies of 
oncogenic KRAS is the abundant off-target effects of RNAi technology. We highlight 
approaches to address this at the analysis stage (using algorithms to account for 
miRNA-like off-target seed effects, filtering by gene expression, and integrating RNAi 
and CRISPR/Cas9 screening data) and at the validation stage (using seed-control 
shRNAs, orthogonal modes of genetic perturbation, and ORF rescue). 
Aside from genotype-specific synthetic lethal interactions, drug-conditional 
synthetic lethal interactions hold much promise for the identification of rational 
combination therapy regimens. Our analysis of genome-scale CRISPR-Cas9 screens 
for genetic modulators of sensitivity to MAPKi indicates that suppression of the DOCK5-
RAC1 pathway may enhance sensitivity to MAPKi in RAS-mutant cancers. Notably, 
recent CRISPR-Cas9 screens in hematopoietic cells identified the RAC1 pathway to be 
selectively essential in RAS-mutant hematopoietic cancers14. Further evaluation of the 
effect of perturbing DOCK5-RAC1 pathway activity in combination with MAPKi may 
unveil a tractable therapeutic target.  
Synthetic lethality is a simple genetic concept that continues to have a major 
impact on cancer research. Direct screening of human cancer cell lines have identified 
synthetic lethal interactions with oncogenic KRAS that have enhanced our 
understanding of oncogenic KRAS signaling and informed novel therapeutic 
strategies3,161,198-200. The small number of cell lines screened and the experimental 
artifacts associated with RNAi off-target effects have limited the power of prior studies. It 
is likely that the use of expanded RNAi libraries with improved analysis techniques to 
estimate off-target effects as well as orthogonal CRISPR/Cas9 knockout libraries in an 
expanded collection of cell lines will enable the discovery of novel synthetic lethal 
interactions that are relevant across broad contexts. 
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Materials and methods 
 
Analysis of Project Achilles v2.4 (shRNA) 
The generation of the Project Achilles v2.4 dataset has been previously described12, 
and was analyzed at the shRNA level and gene level. Gene level data was generated 
using ATARiS (Analytic Technique for Assessment of RNAi by Similarity)139. Data was 
analyzed by two-class comparison using PARIS12, an algorithm that uses a mutual 
information based metric to rank sample data (shRNA/gene dependency) based on the 
degree of correlation to a classification scheme (KRAS mutation status). Analyses were 
performed in which carcinoma cell lines were classified by 1) KRAS mutation status; 2) 
KRAS mutation status and KRAS dependency as determined by KRAS ATARiS score 
(cell lines with KRAS ATARiS score < -0.875 were considered to be KRAS dependent); 
3) KRAS mutation status and KRAS dependency as determined by the shKRAS-3 
shRNA that was previously shown to effectively deplete KRAS3(cell lines with shKRAS-
3 ZMAD score < -0.77 were considered to be KRAS dependent). shRNAs or genes with 
an FDR < 0.25 were considered to be statistically significant. shRNA on-target effects 
were determined using DEMETER11, an recently developed algorithm that models the 
effects produced by individual shRNAs as a linear combination of gene-related effects 
and seed-related effects. We used DEMETER on the Project Achilles v2.4 dataset to 
quantify the on- and off-target effects of individual shRNAs. High priority candidate 
genes were those which had at least 2 shRNAs with an estimated on-target effect of 
>50%.  
 
Analysis of Project Achilles v3.6.2 (CRISPR/Cas9) 
The Project Achilles v3 (CRISPR/Cas9) dataset was recently published15. Here, we 
analyzed a preliminary dataset (Project Achilles v3.6.2). Briefly, Cas9-expressing cells 
were infected with the genome scale Avana pooled CRISPR library141, in which each 
gene is targeted by 4 different gRNA constructs. After puromycin selection, cells are 
passaged for 14 days. At this time, genomic DNA is harvested, and the change in gRNA 
representation compared to the original gRNA plasmid pool is determined. Gene-level 
data was generated using ATARiS139, and data was analyzed by two-class comparison 
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using PARIS. Carcinoma cell lines were classified by KRAS mutation status, and genes 
with an FDR < 0.25 were considered to be statistically significant. 
 
Analysis of CCLE RNA-sequencing expression data 
Cell line RNA-sequencing data was obtained from the Cancer Cell Line Encyclopedia 
164and analyzed using GENE-E, a matrix visualization and analysis platform developed 
by Joshua Gould (http://www.broadinstitute.org/cancer/software/GENE-E/). The 889 
carcinoma cell lines were classified by KRAS mutation status (130 KRAS-mutant and 
759 KRAS-WT), and differentially regulated genes were identified using the “Signal to 
Noise” metric; genes with a FDR < 0.05 were considered statistically significant.  
 
CRISPR/Cas9 + MAPKi drug modifier screen data 
The CRISPR/Cas9 drug modifier screens were recently published172,173. Briefly, for each 
screen, two infection replicates were performed with 30-40% infection efficiency and an 
average of 500 cells per gRNA after selection. 24 hours after infection, cells were 
selected in 2 µg/mL puromycin for 6 days and expanded in puromycin-free media for 4 
days (PATU8988T) or 7 days (PATU8902, CALU1, HCC364, and NCIH1299). After 
puromycin selection, for CALU1, HCC364, and H1299, 60 x 106 cells were harvested for 
the Day 0 time point, and 60 x 106 cells were treated with drug. HCC364 cells were 
treated with 25 nM trametinib or 6.25 %M vemurafenib; H1299 cells were treated with 
1.5 %M trametinib; and CALU1 cells were treated with 50 nM trametinib. For PATU8902, 
75 x 106 cells were seeded in T225 flasks in media without drug on Day -1. Cells were 
allowed to adhere for 24 hours, and 100 nM trametinib was added to the cells on Day 0. 
For PATU8988T, 40 x 106 cells were seeded in T225 flasks with 10 nM trametinib on 
Day 0. Cells were passaged in drug or fresh media containing trametinib was added 
every 3-4 days. Drug-treated cells were harvested 14 days (all cell lines) and 21 days 
(CALU1, HCC364, H1299, and PATU8902) after initiation of trametinib treatment. 
Genomic DNA was extracted using the Qiagen Blood and Cell Culture DNA Maxi Kit 
according to the manufacturer’s protocol. PCR of gDNA and pDNA (gRNA plasmid pool 
used to generate virus) was performed as previously described141. Sequencing and 
analysis of genome scale CRISPR-Cas9 knockout screens was performed as 
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previously described141. The log2(fold-change) in gRNA representation between cells 
treated with trametinib for 14 or 21 days and baseline sample (Day -3 sample for 
PATU8988T, Day -1 sample for PATU8902, and Day 0 sample for CALU1, HCC364, 
and NCIH1299) was calculated.   
 
Cell lines and reagents 
Cells were maintained in DMEM (BXPC3, HPAC, HPAFII, PATU8902, PATU8988T, 
RKO, YAPC; Corning) or RPMI-1640 (NCIH1437, PANC0327; Corning) supplemented 
with 2 mM glutamine, 50 U/mL penicillin, 50 U/mL of streptomycin (Gibco), and 10% 
fetal bovine serum (Sigma), and incubated at 37°C in 5% CO2. 
 
Virus production 
293T cells were seeded in 6 cm dishes. 24 hours later, cells were transfected with 100 
ng VSVG, 900 ng delta8.9, and 1 %g ORF, shRNA or gRNA plasmid using OptiMEM 
and Mirus TransIT. Culture supernatants containing lentivirus was harvested 48 – 72 
hours after transfection. Virus was pooled and stored at -80&°C. 
 
Generation of isogenic cell lines 
To generate cell lines stably expressing Cas9, cells were infected with the Cas9 
expression vector pXPR_BRD111 and selected with 10 %g/mL blasticidin for 4-7 days. 
Cas9-expressing cells were maintained in 2-5 %g/mL blasticidin. To generate isogenic 
cell lines using the CRISPR/Cas9 system, 200,000 Cas9-expressing cells per well were 
seeded in 6-well plates in 2 mL media with 8 %g/mL polybrene. 100-200 %L virus 
(gControl, gGFP, gCOG2, or gDOCK5) was added per well and plates were spun for 30 
minutes at 2250 rpm at 30°C. 24 hours later, cells were selected with 2 %g/mL 
puromycin for 2-3 days. Cells were passaged for a minimum of 7 days after infection 
before use in subsequent experiments. To generate cells that constitutively express a 
particular shRNA, parental cells were infected as described and selected with 2ug/mL 
puromycin for 2-3 days; shRNA-expressing cells were used in subsequent experiments 
4 days after infection. Lysates were collected 4 days after shRNA expression to assess 
gene suppression. To generate cells expressing exogenous COG2 or LacZ, 300,000 
!6O!
cells per well were seeded in 6-well plates in 2 mL media with 8 %g/mL polybrene. 1mL 
virus (COG2-V5 or LacZ-V5) was added per well and plates were spun for 30 minutes 
at 2250 rpm at 30°C. 24 hours later, cells were selected with 10 %g/mL blasticidin for 4 
days. COG2 and LacZ expression was confirmed by immunoblot >7 days after infection. 
 
Crystal violet proliferation assay 
Cells were infected with the indicated shRNAs and selected in puromycin for 4 days. 
Subsequently, cells were seeded in 24-well plates at a density of 10,000-20,000 cells 
per well. Media was changed every 3 days. 6 hours after seeding (Day 0) and 5-8 days 
after seeding, cells were fixed with 10% formalin and stained with 0.5% crystal violet in 
10% ethanol for 20 minutes. After acquiring images, crystal violet uptake was extracted 
with 10% acetic acid and quantified by measuring absorbance at 565 nm using a 
SpectraMax M5 microplate reader (Molecular Devices). 
 
Cell counting assay 
Cells were seeded in 10 cm (1 – 2 x 106 cells) or 15 cm (1 – 3 x 106 cells) plates and 
treated with drug or DMSO as indicated. Cells were propagated or media was refreshed 
every 3 – 4 days. Cells were counted at each passage, and number of cell doublings 
was calculated. 
 
siRNA viability assay 
Negative control (D-001810) and DOCK5-targeting (L-018931) SMARTpool siRNA 
reagent was obtained from Dharmacon. Transfection was performed according to 
manufacturer’s protocol by combining  siRNA (final concentration of 50nM siRNA), 
Dharmafect, and with 4000 cells (293T, HCT116, or PATU8902) per well in white, 
opaque-bottom 96-well plates (Costar, for viability assay) or 6-well plates (for qRTPCR 
and immunoblot analysis). Cells were harvested 2 and days after transfection for 
qRTPCR and immunoblot analysis, respectively.  2, 4, and 6 days after transfection, cell 
viability was assessed using CellTiter-Glo (Promega) according to manufacturer’s 
protocol 
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GFP competition assay 
50,000 PATU8902-Cas9 cells were seeded in 48 well plates in 25uL media with 4 
%g/mL polybrene. 25uL virus (pRosetta-GFP, gGFP, or gDOCK5) was added per well 
and plates were spun for 2 hours at 2,000 rpm at 30°C. after 6 hours, cells were split 
into a 10cm dish. 24 hours after infection, cells were selected with 2%g/mL puromycin 
for 8 days, passaging when necessary. 10 days after infection, GFP-expressing cells 
were mixed with gRNA-expressing cells in a 1:1 ratio. This cell mixture was analyzed by 
FACS to determine the baseline proportion of GFP-positive cells. Cells were seeded in 
15cm plates (3E6 cells for DMSO-treated plates, 8E6 cells for trametinib-treated plates) 
in duplicate. Cells were treated with 50nM trametinib or DMSO. DMSO cells were 
passaged every 3 days. The media of trametinib-treated cells was refreshed after 3 
days and passaged after 6 days. Percent GFP-positive cells was assessed via FACS on 
day 6 and day 12 after seeding.   
 
Quantitative PCR 
RNA was isolated using an RNeasy kit (Qiagen). cDNA was synthesized using 
Superscript III First-Strand Synthesis Supermix for qRT-PCR (Invitrogen), and analyzed 
by quantitative PCR (q-PCR) using Power Sybr Green PCR Master Mix (Invitrogen) on 
a QuantStudio 6 Flex PCR system (Applied Biosystems) according to the 
manufacturer’s recommendations. Target gene expression was normalized to GAPDH 
expression, and shown relative to control samples. Primer sequences used for q-PCR: 
 
qRTPCR primer sequences 
Gene Forward Primer Reverse Primer 
COG2 AAACCTCTGCACTAGAAGCAAG GCTATACGCGGTCTTACTTTGTC 
DOCK5 CCCTCGTACATCTCCAGGAT ACCAAGAGGCAGAAGTACGG 
GAPDH CCTGTTCGACAGTCAGCCG CGACCAAATCCGTTGACTCC 
KRAS CAGTACAGTGCAATGAGGGAC CCTGAGCCTGTTTTGTGTCTAC 
 
Immunoblots and antibodies 
COG2, KRAS, ERK, AKT, '-Actin, and GAPDH immunoblots were performed by 
separating 10 – 40 µg cell lysate per sample on a 4%-12% Bis-Tris gel (Invitrogen 
!6E!
NuPage) and transferring to nitrocellulose membrane using the iBlot system (Life 
Technologies). Primary antibodies were obtained from Abcam (COG2 ab167416), Cell 
Signaling (GAPDH #2118, total ERK #9102, phospho-ERK #4370, total AKT #9272, 
phosphor-AKT #4060), Proteintech (KRAS 12063-1-AP), Santa Cruz Biotechnology ('-
Actin sc-47778), and Sigma Aldrich (KRAS WH0003845M1). Immunoblots were 
visualized by infrared imaging (LI-COR). Protein quantification was performed according 
to manufacturer’s recommendation (LI-COR), and expression was normalized to a 
control gene (GAPDH or '-Actin). 
 
Vectors 
LacZ and COG2 in the pLX304 backbone and Cas9 in the pLX311 backbone 
(pXPR_BRD111) were obtained from the Genetic Perturbation Platform at the Broad 
Institute. shRNAs in the pLKO.1 backbone and gRNAs in the pXPR_BRD003 backbone 
were cloned as recommended by the Genetic Perturbation Platform at the Broad 
Institute. shRNA gRNA sequences are listed below. 
 
shRNA sequences 
Vector Name Sequence 
shControl ACACTCGAGCACTTTTTGAAT 
pLKO1_shKRAS-1 CCTATGGTCCTAGTAGGAAAT 
pLKO1_shKRAS-2 GAGGGCTTTCTTTGTGTATTT 
pLKO1_shKRAS-3 CCTCGTTTCTACACAGAGAAA 
pLKO1_shKRAS-4 CAGTTGAGACCTTCTAATTGG 
pLKO1_shCOG2-1 CGAACTCATCAACAAGGATTA 
pLKO1_shCOG2-2 CCATACATAGACGAGGTGATT 
pLKO1_shCOG2-3 CCTGCCTATCACAGCTTCAAT 
pLKO1_shCOG2-4 CGGAAACAAAGCCTGTGGTTT 
pLKO1_shCOG2-5 GCACTCATAAGTACTATGAAA 
pLKO1_shCOG2-6 GCGTCTTCTCTCAGCGTATTT 
pLKO1_shCOG2-7 GACCTGGAGCTCTACTATAAA 
pLKO1_shCOG2-8 ATTGAGGCTTATACAAGTTAT 
pLKO1_shCOG2-9 AGACGTCTGACGTCGATATAA 
pLKO1_shCOG2-10 TGGATCACAGGCTAGTGTAAA 
pLKO1_shDOCK5-1 GCGACTAATAGCATTACAGAT 
pLKO1_shDOCK5-2 AGTACCTTCCTAGCATAATTA 
pLKO1_shDOCK5-3 GCCACTCACTTCAGTCTTGAA 
pLKO1_C911-shKRAS-1 CCTATGGTAGGAGTAGGAAAT 
pLKO1_C911-shKRAS-2 GAGGGCTTAGATTGTGTATTT 
!<P!
pLKO1_C911-shKRAS-3 CCTCGTTTTAGCACAGAGAAA 
pLKO1_C911-shKRAS-4 CAGTTGAGGGTTTCTAATTGG 
pLKO1_C911_shCOG2-1 CGAACTCATGAACAAGGATTA 
pLKO1_C911_shCOG2-2 CCATACATTCTCGAGGTGATT 
pLKO1_C911_shCOG2-3 CCTGCCTATGACAGCTTCAAT 
pLKO1_C911_shCOG2-4 CGGAAACACTTCCTGTGGTTT 
pLKO1_C911_shCOG2-5 GCACTCATCTTTACTATGAAA 
pLKO1_C911_shCOG2-6 GCGTCTTCAGACAGCGTATTT 
pLKO1_C911_shDOCK5-1 GCGACTAACTACATTACAGAT 
pLKO1_C911_shDOCK5-2 AGTACCTTAGGAGCATAATTA 
pLKO1_C911_shDOCK5-3 GCCACTCAAAGCAGTCTTGAA 
 
gRNA sequences 
Vector Name Sequence 
gControl ACACTCGAGCACTTTTTGAAT 
gGFP A02 GGCGAGGGCGATGCCACCTA 
gGFP B09 GGTGCCCATCCTGGTCGAGC 
gKRAS-1 AACATCAGCAAAGACAAGAC 
gKRAS-2 CAATGAGGGACCAGTACATG 
gKRAS-3 TTTGCTGATGTTTCAATAAA 
gDOCK5-1 ACTTACCCTCGTACATCTCC 
gDOCK5-2 CCTCCAAAATAAATCTAAAA 
gDOCK5-3 CGGTGACACAGTTCACATCC 
gDOCK5-4 GCTCTGACAGGTTGGTACAG 
gDOCK5-5 AACATATATCCATTTGAAAG 
gDOCK5-6 CCACAGTTGCCTCTTTCAAA 
 
 !
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Tables !
Table 1. Frequency of RAS mutations in human cancers. 
Cancer % KRAS  % NRAS % HRAS % RAS 
Pancreatic ductal adenocarcinoma 97.7 0 0 97.7 
Colorectal adenocarcinoma 44.7 7.5 0 52.2 
Multiple myeloma 22.8 19.9 0 42.6 
Lung adenocarcinoma 30.9 0.9 0.3 32.2 
Skin cutaneous melanoma 0.8 27.6 1 29.1 
Uterine corpus endometrioid carcinoma 21.4 3.6 0.4 24.6 
Uterine caricinosarcoma 12.3 1.8 0 14.3 
Thyroid carcinoma 1 8.5 3.5 12.5 
Acute myeloid leukemia 3.1 6.7 1.6 11.4 
Bladder urothelial carcinoma 3.1 1.4 5.9 10.6 
Gastric adenocarcinoma 11.4 0.9 0 10 
Cervical adenocarcinoma 8.3 0 0 8.3 
Head and neck squamous cell 
carcinoma 
0.5 0.3 4.7 5.5 
Diffuse large B cell lymphoma 5.2 0 0 5.2 
Adapted from Cox et al. (2014)33, where data were compiled from a variety of sources, 
including but not limited to The Cancer Genome Atlas, the International Cancer 
Genome Consortium, and cBioPortal201,202. !!
Table 2. RAS synthetic lethal genes. 
Synthetic 
lethal genes 
or pathways 
Library (assay and 
format) 
Cells in primary 
screen 
Drug inhibition References 
RAN, TPX2, 
SCD1 
~3,700 druggable genes, 
siRNA, arrayed cell death 
NCIH1299 
(NRASQ61K NSCLC) 
Not tested Morgan 
Lappe et al. 
2007203 
BIRC5 
(survivinn), 
CDK1, 
RBCK1 
~4,000 genes, siRNA, 
arrayed cell death 
Isogenic DLD1 
(CRC, KRASG13D) 
Not tested Sarthy et al. 
2007204 
PLK1, 
APC/C, 
proteosome 
Genome scale, shRNA, 
pooled proliferation 
screen with microarray 
readout 
Isogenic DLD1 
(CRC, KRASG13D) 
BI-2536 Luo et al. 
20094 
STK33, 
AKT3, 
CPNE1, 
CAMPK1, 
MLKL, 
FLT3LG, and 
DGKZ 
~1,000 druggable genes, 
shRNA, arrayed 
proliferation 
Pan-cancer cell line 
panel (4 KRAS-
mutant, 4 KRAS-
wildtype) and 2 
immortalized cell 
lines 
STK33 kinase 
inhibitor, failed to 
suppress 
proliferation in 
KRAS-mutant cells 
205-207 
Scholl et al. 
20098 
TBK1, 
PSKH2, 
PTCH2, 
CPNE1, 
MAP3K8, 
~1,000 druggable genes, 
shRNA, arrayed 
proliferation 
Pan-cancer cell line 
panel (7 KRAS-
mutant, 10 KRAS-
wildtype) and 2 
immortalized cell 
CYT387 (TBK1 
and JAK inhibitor), 
assessed in 9 
Barbie et al. 
20093 
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proteasome lines 
WT1, RAC1, 
PHB2 
162 KRAS related genes, 
shRNA, in vitro and in 
vivo pooled proliferation 
screens with bead array 
readout 
LKR10 and LKR13 
(Kras;Trp53 mutant 
mouse lung tumor 
derived cell lines) 
Not tested Vicent et al. 
20105 
SNAI2 
(SNAIL2) 
~2,500 druggable genes, 
shRNA, pooled 
proliferation with 
microarray readout 
Isogenic HCT116 
(CRC, KRASG13D) 
Not tested Wang et al. 
20106 
GATA2, 
CDC6, 
proteasome 
~8,000 druggable genes, 
siRNA, arrayed apoptosis 
and cell proliferation 
Isogenic HCT116 
(KRASG13D) and 
pan-cancer cell line 
panel (14 KRAS-
mutant, 12 KRAS-
wildtype) 
Bortezomib with 
fasudil (GATA2)  
Kumar et al. 
2012146 
Steckel et al. 
2012147 
MAP3K7 
(TAK1) 
17 kinases highly 
expressed in KRAS-
dependent CRC, shRNA, 
arrayed proliferation 
KRAS-dependent 
SW620 and KRAS-
independent 
SW837 (CRC, 
KRAS-mutant) 
5Z-7-oxozeaenol Singh et al. 
2012208 
Cttnb1 ('-
catenin), Mllt6 
Genome scale, shRNA, 
pooled in vivo 
proliferation with NGS 
readout 
Mouse 
keratinocytes 
(HrasG12V) 
Not tested Beronja et al. 
2013209 
COP1 
coatomer 
Genome scale, siRNA, 
arrayed proliferation 
17 KRAS- and 
LKB1-mutant lung 
cancer cell lines, 
matched tumor 
(KRAS-mutant) and 
normal NSCLC cell 
line pair 
Saliphenylhalamide 
A 
Kim et al. 
2013210 
ARHGEF2 
(GEFH1) 
Genome scale, shRNA, 
pooled proliferation with 
NGS readout 
Pan-cancer panel 
(72 cell lines).  
Not tested Marcotte et 
al. 2012166 
Cullis et al. 
2014211 
BCL2L1 
(BCLXL) 
~1,200 druggable genes 
in presence of MEK 
inhibitor (selumetinib), 
shRNA, pooled 
proliferation with NGS 
readout, synergistic 
death with MEK inhibitor 
HCT116 and 
SW620 (CRC, 
KRAS-mutant) 
Selumetinib and 
navitoclax 
Corcoran et 
al. 2013162 
 
CDK1 784 genes, siRNA  
(Dharmacon 
SMARTPool), arrayed 
proliferation 
Isogenic LIM1215 
(CRC, KRAS-WT) 
RO-3306 (CDK1 
inhibitor), AZD5438 
(CDK1/2 and 9 
inhibitor) 
Costa-Cabra; 
et al. 2016212 
RCE, ICMT, 
RAF1, 
SHOC2, 
PREX1 
Genome scale, gRNA, 
pooled proliferation with 
NGS readout 
12 human AML cell 
lines (6 RAS-
mutant, 6 RAS-
WT), BaF3 cells 
(mouse, NRAS-WT) 
FRAX-597 (PAK 
inhibitor) 
Wang et al. 
201714 
Abbreviations: NSCLC (non-small cell lung cancer), CRC (colorectal cancer), NGS 
(next-generation sequencing). Table from Wang 2016213. 
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Table 3. KRAS-mutant co-dependencies. 
Gene FDR DM Marcotte et al. 
KRAS < 0.0001 -1.0379 Yes 
COG2 < 0.0001 -0.7876 Yes 
MEST 0.02222 -0.5692 No 
TXNDC8 0.06667 -0.4931 No 
RHOV 0.09333 -0.4898 No 
ABP1 0.1333 -0.4983 No 
RGS2 0.1333 -0.6031 No 
ZBTB48 0.1926 -0.487 No 
FERMT1 0.1926 -0.5555 Yes 
 
FDR- ranked list of genes essential for proliferation/survival of KRAS-mutant cells. 
Column guide: FDR (false discovery rate q-value); DM (difference in mean gene 
dependency score between KRAS-mutant and KRAS-WT cell lines, where a negative 
score reflects preferentially negative effect on proliferation/viability for KRAS-mutant cell 
lines); Marcotte et al. (identification as a significant candidate in analysis of the 
independent Marcotte et al. 2012 dataset of 72 cancer cell lines166). !!
Table 4. KRAS classification schemes. 
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Carcinoma cell lines screened in Project Achilles v2.4 were classified by KRAS mutation 
status and KRAS dependency status (assessed by shKRAS 509 or KRAS ATARiS 
score). Numbers refer to the number of cell lines in each classification.!!!!!!!!!!!!!
!<<!
Table 5. Candidate co-dependencies in KRAS-mutant cells 
Gene Mutation Mut + shKRAS Mut + ATARiS On-target 
KRAS X X X X 
COG2 X X X  
MEST X X X  
TXNDC8 X X X  
RHOV X X X  
ABP1 X X X  
RGS2 X X X  
ZBTB48 X X X  
FERMT1 X X X  
ALDH9A1 X X X  
DOCK5 X X X  
GPR182 X X X  
CELF6 X X X  
TMX3 X X X  
KIRREL3 X X X  
HBG1 X X X  
NOTCH2 X X X  
NCOR2 X X X  
RGL1 X X X  
FLT3 X X X  
IFI16 X X X  
API5 X X X  
GTF3A X X X X 
SCN5A X X X  
CD58 X X X  
ATP2B4 X X X  
DHPS X X X  
BCL2L1 X X X X 
TASP1 X  X  
APOE X  X X 
PNO1 X  X  
CDK6  X X  
JUNB  X X  
HIATL1  X X X 
MED30  X X X 
RAF1 (CRAF)  X X  
CDA  X   
RPS15A  X  X 
CTNNB1  X X  
SCAP   X X 
EPRS   X X 
PRKAG3   X  
ZPLD1   X  
HDAC3   X  
CXCL6   X  
VPS28   X X 
NOG   X  
!<>!
PIK3CA   X X 
MTOR   X X 
MAPK1   X  
MAP2K1   X  
PLK1   X  
MAP3K7 (TAK1)   X  
WT1   X  
CDK2   X X 
BCL2   X  
MYC   X X 
RPS6   X  
MCL1   X  
(
Genes that are selectively essential in KRAS-mutant cell lines as determined by two 
class comparisons in which cell lines were classified by KRAS mutation status 
(“Mutation”), by KRAS mutation status and KRAS dependency as measured by the 
shKRAS 509 shRNA (“Mut + shKRAS”), or by KRAS mutation status and KRAS 
dependency as measured by KRAS ATARiS score (“Mut + ATARiS”). Significant genes 
(FDR < 0.25) are marked by an ‘X.’  “On-target” indicates that the gene had at least 2 
shRNAs that were estimated to have an on-target effect of > 50% by DEMETER11. 
Genes that have been previously identified as co-dependencies in KRAS-mutant cells 
are shaded in gray. !!! !
!<C!
Figures !
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Figure 1. The RAS pathway. RTKs are activated by extracellular ligand binding, which 
induces dimerization and trans-phosphorylation of intracellular tyrosine residues. The 
adaptor protein GRB2 binds to the phospho-tyrosine site on RTKs and to cytosolic 
GEFs. RAS proteins are activated by GEFs and inactivated by GAPs. RAS missense 
mutations, which primarily arise in resides G12, G13, and Q61, impair intrinsic and/or 
GAP-stimulated GTPase activity. Key RAS effectors include the MAPK , PI3K, and 
RAL-GEF pathways. Abbreviations: RTK (receptor tyrosine kinase), GEF (guanine 
nucleotide exchange factor), GAP (GTPase activating protein), PIP3 
(phosphatidylinositol 3,4,5-bisphosphate), PIP2 (phosphatidylinositol 4,5-bisphosphate). 
Figure from Wang (2016)213. 
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Figure 2. Strategies to target mutant RAS. Major pharmacologic approaches to inhibit 
oncogenic RAS include inhibiting upstream RAS activators, such as RTKs; directly 
targeting RAS at its GTP-binding pocket or interfering with the RAS–SOS or RAS–RAF 
interaction; preventing RAS membrane localization of by inhibiting RAS prenylation with 
FTIs (farnesyltransferase inhibitors) or GGTIs (geranyl geranyltransferase inhibitors), or 
by inhibiting PDE$ (phosphodiesterase $); inhibiting downstream RAS effectors using 
RAF, MEK, ERK, or PI3K pathway inhibitors; and inhibiting RAS synthetic lethal 
interactors. Figure from Wang (2016)213. !!
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Figure 3. Synthetic lethality in cancer. (A) The loss or inhibition of gene A or gene B 
alone or the overexpression of gene A have no effect on viability. However, mutation (B) 
or pharmacologic inhibition of the protein product of gene B in cells that harbor a 
mutation (B, C) or overexpressioon (D) of gene A results in synthetic lethality. Star 
indicates mutation, red cross indicates pharmacologic inhibition, and thick arrow 
indicates overexpression. Figure adapted from O’Neil et al. (2017)115.!
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Figure 4. Experimental approaches to synthetic lethality screens in cancer cell 
lines. (A) Human synthetic lethality screens most commonly use either pairs of 
matched isogenic cell lines derived from the same parental cell line which differ only in 
the gene of interest (Ai) or a panel of genetically diverse cell lines that are split into two 
groups depending o the mutation status of the gene of interest (Aii). (B) In arrayed 
format screens, cells are seeded in 96-, 384-, or 1536-well plates. Each well is 
transfected with an individual siRNA or infected with an individual shRNA or gRNA. 
After a period of time, the number of cell in each well is quantified, and genes that are 
specifically essential in KRAS-mutant cells can be identified. (C) In pooled format 
screens, cells are infected with a pooled lentivirus shRNA or gRNA library, and a 
baseline sample of gDNA is obtained. Cells populations are grown and next-generation 
sequencing technologies are used to identify sequences that are underrepresented 
specifically in the cell lines that harbor the mutant gene of interest. Genes targeted by 
multiple shRNAs or gRNAs in this subset are candidate synthetic lethal (SL) interactions 
for the mutant gene of interest. Figure adapted from O’Neil et al. (2017)115. 
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Figure 5. Drug-conditional synthetic lethal interactions. Synthetic lethal interactions 
may be dependent on specific conditions such as the presence of a chemical inhibitor. 
(A) In normal cells or cancer cells with a mutation in gene 1, the loss of gene 2 or 
pharmacologic inhibition gene 2 has no effect on viability. However, when gene 3 is 
inhibited pharmacologically, mutation or pharmacologic inhibition of gene 2 does not 
affect viability in normal cells (B), but is synthetic lethal to cells with mutant gene 1 (C). 
Star indicates mutation, red cross indicates pharmacologic inhibition of protein product 
or genetic knockout. 
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Figure 6. Project Achilles overview and analysis. Genome scale negative selection 
screens to identify synthetic lethal interactions with oncogenic KRAS. In Project 
Achilles, cells are infected with a pooled genome-scale shRNA library, selected, and 
propagated for 16 doublings. shRNA abundance at the endpoint relative to the baseline 
reference is assessed by massively parallel sequencing. Depleted shRNAs target genes 
whose suppression impairs cell proliferation/survival. For Project Achilles, shRNA-level 
data can be analyzed directly or converted to gene-level dependency scores using the 
ATARiS method139. Cell lines are classified by KRAS mutation status or KRAS 
dependency, and a two-class comparison is performed using PARIS (Probability 
Analysis by Ranked Information Score), a mutual information-based algorithm12, to 
identify genes that are selectively essential for the survival of KRAS-mutant cells. 
Significance (FDR q-value) is determined by permuting class labels.  
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Figure 7. KRAS mutation status does not always predict KRAS dependency. The 
KRAS dependency of the cell lines screened in Project Achilles v2.4 was quantified by 
their KRAS ATARiS score139, a value that reflects the aggregate effects of the 10 KRAS 
shRNAs in the screening library. Negative ATARiS scores indicate greater gene 
dependency. 
 
 
 
 
Figure 8. KRAS classifications for two-class comparisons. KRAS mutation status 
and KRAS dependency do not correlate perfectly. Hence, cell lines were classified by 
using 3 separate metrics: (1) KRAS mutation status and sensitivity to KRAS-depletion 
as measured by the KRAS ATARiS score139, a value that reflects the aggregate effects 
of 10 KRAS shRNAs screened in Project Achilles; (2)  KRAS mutation and sensitivity to 
KRAS-depletion by shKRAS 509, a KRAS-targeting shRNA that effectively depletes 
KRAS expression at a protein level3; or (3) only KRAS mutation status. Each bar 
represents an individual cell line screened in Project Achilles v2.4.  
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Figure 9. COG2 shRNAs reduce COG2 expression. RKO (KRAS-WT, colon) cells 
were infected with the indicated shRNAs and selected. COG2 expression was assessed 
by qRT-PCR (A) and immunoblot (B) 6 days post infection. 4 technical replicates 
representative of 2 independent experiments, data represented as mean ± SEM.  !
 
 
Figure 10. COG2 shRNAs decrease proliferation viability in both KRAS-WT and 
KRAS-mutant cells. Crystal violet cell proliferation assay to determine the effect of 
COG2 depletion on cell proliferation/viability. 4 technical replicates, data represented as 
mean ± SEM. 
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Figure 11. Exogenous COG2 expression does not rescue shRNA-mediated COG2 
depletion. (A) Immunoblot analysis of COG2 expression in cell lines expressing COG2-
specific shRNAs and/or exogenous COG2-V5 cDNA. (B) Cell proliferation assay to 
whether exogenous COG2-V5 overexpression could rescue viability upon shCOG2-
mediated suppression of endogenous COG2 expression in HPAC (KRASG12D) cells. 4 
technical replicates representative of 2 independent experiments, data represented as 
mean ± SEM. 
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Figure 12. Additional COG2-targeting shRNAs do not selectively decrease 
proliferation/viability in KRAS-mutant cells. (A) Immunoblot analysis of COG2 
expression. Bold: COG2-targeting shRNAs that were not included in the Project Achilles 
shRNA screen. *COG2-targeting shRNAs that distinguished between KRAS-WT and 
KRAS-mutant cell lines in the Project Achilles screens. (B) Cell proliferation assay to 
determine effect of COG2 depletion on cell proliferation/viability. Checkered bars: 
COG2-targeting shRNAs that were not included in the Project Achilles shRNA screen. 
Light blue bars: COG2-targeting shRNAs that distinguished between KRAS-WT and 
KRAS- mutant cell lines in the Project Achilles screens. 4 technical replicates, data 
represented as mean ± SEM. 
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Figure 13. COG2 is not a specific co-dependency of KRAS-mutant cell lines. (A) 
Design of C911 seed-control shRNAs, in which the three nucleotides at position 9 to 11 
of the shRNA target sequence (black) are converted to their reverse complement 
(yellow)167. (B) Cell proliferation assay to determine seed effects of shRNAs targeting 
COG2 and KRAS using C911 seed control shRNAs. 4 technical replicates, data 
represented as mean ± SEM. (C) Immunoblot analysis of KRAS and COG2 depletion.  
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Figure 14. CRISPR/Cas9-mediated COG2 knockout does not affect viability in 
KRAS-mutant cells. (A) Immunoblot analysis of COG2 and KRAS expression in 
NCIH1437-Cas9 and YAPC-Cas9 cells expressing the indicated gRNAs. Cells were 
infected with gRNA constructs and selected. Lysates were harvested 7 days post 
infection. (B) Crystal violet proliferation assay to determine effect of COG2 and KRAS 
knockout on cell viability. 4 technical replicates representative of 2 independent 
experiments, data represented as mean ± SEM.  
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Figure 15. Approaches to prioritize candidate co-dependencies of oncogenic 
KRAS identified by analyzing Project Achilles shRNA data. (A) Prioritize genes 
whose expression is upregulated in KRAS-mutant cell lines. (B) Select genes that are 
also found to be selectively essential in KRAS-mutant cells in Project Achilles CRISPR-
Cas9 data. (C) Filter for genes for which at least two shRNAs have >50% on-target 
effect as assessed by DEMETER11. 
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Figure 16. DOCK5 expression is upregulated in KRAS-mutant cell lines. In RNA-
sequencing data of cell lines in the Cancer Cell Line Encyclopedia164, DOCK5 is 
significantly more highly expressed in the 130 KRAS-mutant compared to 769 KRAS-
WT carcinoma cell lines (t-test, p < 0.001). 
 
 
Figure 17. shRNAs targeting DOCK5 also reduce KRAS expression. (A) Effect of 
DOCK5 suppression on cell viability. Cells were infected with the indicated shRNAs, 
selected, and seeded in 96-well plates in quadruplicate 4 days post infection. Cell 
viability was measured by CellTiter-Glo 9 days post infection (5 days post seeding) and 
normalized to the number of cells seeded. Two representative cell lines are depicted. 4 
technical replicates, data represented as mean ± SEM. (B) Effect of the indicated 
shRNAs on DOCK5 and KRAS expression (qRT-PCR) in NCIH1437 (KRAS-WT) cells. 
4 technical replicates, data represented as mean ± SEM.  
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Figure 18. DOCK5 shRNAs decrease KRAS expression via off-target effects. qRT-
PCR evaluation of DOCK5 (A) and KRAS (B) expression in in HCT116 (KRAS-mutant, 
colon) cells expressing the indicated shRNAs. C911 indicates seed-control shRNAs, in 
which the three nucleotides at position 9 to 11 of the shRNA target sequence are 
converted to their reverse complement167, which abrogates ‘on-target’ depletion of 
target mRNA while preserving ‘off-target’ seed effects. 4 technical replicates, data 
represented as mean ± SEM. (C) Immunoblot analysis of KRAS expression in HCT116 
cells expressing the indicated shRNAs. (D) Effect of DOCK5 suppression on cell 
viability. Cells were infected with the indicated shRNAs, selected, and seeded in 96-well 
plates in quadruplicate 4 days post infection. Cell viability was measured by CellTiter-
Glo 10 days post infection (6 days post seeding) and normalized to the number of cells 
seeded. 3 technical replicates, data represented as mean ± SEM.  
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Figure 19. siRNA-mediated DOCK5 depletion does not affect KRAS expression or 
viability. HCT116 (KRAS-mutant, colon) cells were transfected with Dharmacon 
SMARTpool control (siNonTargeting) or DOCK5-targeting siRNAs. After 48 hours, 
expression of DOCK5 (A) and KRAS (B) was determined by qRTPCR. KRAS 
expression was also assessed by immunoblot (C). (D) Cell viability was measured by 
CellTiter-Glo 6 days post transfection. 3 technical replicates, data represented as mean 
± SEM. 
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Figure 20. CRISPR-mediated DOCK5 knockout does not affect KRAS expression 
or cell viability. PATU8902-Cas9 cells were infected with the indicated gRNAs and 
selected. 8 days post gRNA infection, expression of DOCK5 (A) and KRAS (B) were 
assessed using q-RTPCR. 4 technical replicates representative of 2 independent 
experiments, data represented as mean ± SEM. (C) Effect of DOCK5 knockout on 
KRAS expression and MAPK pathway activity was evaluated by immunoblot. (D) Effect 
of DOCK5 knockout on cell viability was assessed using a crystal violet assay. Cells 
were seeded in 6 well plates 8 days post gRNA infection. Cells were fixed and stained 
with crystal violet 8 days post seeding (DPS). 4 technical replicates representative of 2 
independent experiments, data represented as mean ± SEM. (E) Cell counting assay to 
determine the effect of DOCK5 knockout on cell proliferation. Cells were seeded in 
10cm plates 20 days post gRNA infection. Cells were counted and passaged every 3-4 
days. 2 technical replicates representative of 2 independent experiments, data 
represented as mean ± SEM.  
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Figure 21. DOCK5 modulates sensitivity to MAPK pathway inhibition. (A) Outline of 
strategy for pooled genome-scale CRISPR-Cas9 screens in RAS- or BRAF-mutant 
cancer cell lines treated with MAPK pathway inhibitors. (Bi) Distribution of log2 fold-
change in gRNA representation on day 14 versus day 0 of PATU8902 cells treated with 
100nM trametinib. Average of two biological replicates. Gray lines indicate the average 
log2 fold-change (solid) or 4 SD above average log2 fold-change (dashed) of all 
screened gRNAs. gRNAs targeting DOCK5 (red), RAC1(orange), and KRAS (green) 
!C<!
are indicated. log2 fold-change of top 15 most enriched gRNAs are indicated in (Bii). 
(Ci) Schematic of DOCK5 structure. At baseline, the N-terminal SH3 domain of DOCK5 
interacts with its C-terminal DHR2 domain, autoinhibiting GEF activity. Interaction 
between SH3 domain and ELMO1 abrogates autoinhibition. DHR1 domain mediates 
interactions with lipids (PIP3). DHR2 interacts with RAC1 and promotes the exchange of 
GDP for GTP. (Cii) DOCK5-targeting gRNAs that became strongly enriched in 
PATU8902 cells treated with the MEK inhibitor trametinib target theDOCK5 N-terminal 
SH3 domain (red). DOCK5-targeting gRNAs that did not become enriched in the 
PATU8902 screen (purple) or in other screens of RAS-mutant cells treated with MAPK 
pathway inhibitors (gray) target regions downstream of the SH3 domain. 
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Figure 22. DOCK5 knockout sensitizes cells to MAPK pathway inhibition. (A) 
gRNAs targeting DOCK5, RAC1, and KRAS are depleted in the majority  genome-scale 
CRISPR-Cas9 screens. Average log2(fold change) of the 3 most depleted gRNAs 
targeting DOCK5 (blue), RAC1 (red), or KRAS (green) on Day 14 of the indicated 
genome-scale CRISPR-Cas9 screen. Gray bars indicate the average log2(fold change) 
of all gRNAs in the screen. TRAM = trametinib (MEK inhibitor). VEM = vemurafenib 
(BRAF inhibitor) . 2 biological replicates, data represented as mean ± SEM. (B) 
Competition assay demonstrates that DOCK5-knockout cells have reduced 
viability/proliferation compared to parental DOCK5-WT cells. PATU8902 (KRAS-mutant, 
pancreas) cells expressing GFP were mixed with unlabeled PATU8902-Cas9 cells 
expressing the indicated gRNA in a 1:1 ratio. Change in percentage GFP-expressing 
cells was assessed after 6 days. 2 technical replicates representative of 2 independent 
experiments, data represented as mean ± SEM.  
!CC!
 
Figure 23. DOCK5 deletion reduces p-AKT. Immunoblot analysis of expression of the 
indicated proteins in PATU8902 cells (KRAS-mutant, pancreas) treated with DMSO 
(control) or 50nm Trametinib (MEK inhibitor) for 24 hours. 
 
 
Figure 24. Signal convergence downstream of RAS and DOCK5. Proposed model in 
which oncogenic RAS and DOCK5-RAC1 converge to activate the PI3K pathway, which 
promotes cell proliferation and viability. Reduced DOCK5 activity may increase 
sensitivity to MAPK inhibition in RAS-mutant cells by reducing PI3K pathway activity. 
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